Load list of proteins for prioritization
Out of your selected genes:
P02741, P19440, P24298, P25445, Q13478, Q6UWV6, Q96HD1, Q99988, Q9BZR6
the following targets was matched in our database to the gene names:
CRP, GGT1, GPT, FAS, IL18R1, ENPP7, CRELD1, GDF15, RTN4R
Gene synonyms | Protein name | UniProt ID | Subcellular location | Protein family | Protein class | Target development level | |
---|---|---|---|---|---|---|---|
CRELD1 | AVSD2, CIRRIN | Protein disulfide isomerase CRELD1, EC 5.3.4.1 | Q96HD1 | Nucleoli, Cytosol | Non-IDG | Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins | Tbio |
CRP | PTX1 | C-reactive protein [Cleaved into: C-reactive protein | P02741 | Nucleoplasm, Vesicles, Intermediate filaments | Non-IDG | Cancer-related genes, Candidate cardiovascular disease genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins | Tbio |
ENPP7 | alk-SMase, NPP7 | Ectonucleotide pyrophosphatase/ phosphodiesterase family member 7, E-NPP 7, NPP-7, EC 3.1.4.12 | Q6UWV6 | – | Enzyme | Enzymes, Metabolic proteins, Predicted intracellular proteins | Tbio |
FAS | APO-1, APT1, CD95, FAS1, TNFRSF6 | Tumor necrosis factor receptor superfamily member 6 | P25445 | Nuclear bodies, Plasma membrane, Cytosol | Non-IDG | Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Human disease related genes, Metabolic proteins, Predicted membrane proteins, Predicted secreted proteins | Tbio |
GDF15 | MIC-1, MIC1, NAG-1, PDF, PLAB, PTGFB | Growth/ differentiation factor 15, GDF-15 | Q99988 | Golgi apparatus | Non-IDG | Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins | Tbio |
GGT1 | CD224, D22S672, D22S732, GGT | Glutathione hydrolase 1 proenzyme, EC 3.4.19.13 | P19440 | Vesicles | Enzyme | Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins | Tbio |
GPT | ALT1, GPT1 | Alanine aminotransferase 1, ALT1, EC 2.6.1.2 | P24298 | – | Enzyme | Enzymes, Metabolic proteins, Plasma proteins, Predicted intracellular proteins | Tbio |
IL18R1 | CD218a, IL-1Rrp, IL1RRP | Interleukin-18 receptor 1, IL-18R-1, IL-18R1, EC 3.2.2.6 | Q13478 | Mitochondria | Non-IDG | CD markers, Enzymes, Plasma proteins, Predicted membrane proteins | Tbio |
RTN4R | NOGOR | Reticulon-4 receptor | Q9BZR6 | Plasma membrane, Actin filaments, Focal adhesion sites | Non-IDG | Disease related genes, Human disease related genes, Predicted membrane proteins | Tbio |
Table content:
Protein name (UniProt): Name of gene product.
Gene synonyms (HPA): A list of different synonyms (in uppercase) for the (official) gene name provided by HPA.
UniProt ID (UniProt): Link to UniProt for additional information on the target.
Protein class (HPA): Classification of the protein target based on function and cellular compartment and/or disease and drug related information.
Subcellular location (HPA): HPA-assigned subcellular location.
Protein family (PHAROS): Protein family the
target is assigned to. Levels: GPCR, Nuclear Receptor, Kinase, Enzyme,
Ion Channel, Transcription Factor, Transporter, Epigenetic, oGPCR,
TF/Epigenetic, Non-IDG.
Special emphasis is given on four superfamilies that are central to the
NIH IDG initiative: GPCRs, kinases, ion channels, and nuclear
receptors.
Target development level (PHAROS): Target Development Level (TDL) (for more information on TDL see here). TDL categorizes the target based on known information and potential drugability, with descending ranking:
en-dash (-) indicates that no information was available for the target.
Functionality description | Diabetes associations | Suggested biomarker | |
---|---|---|---|
CRELD1 | Description missing | – | No |
CRP | Displays several functions associated with host defense: it promotes agglutination, bacterial capsular swelling, phagocytosis and complement fixation through its calcium-dependent binding to phosphorylcholine. Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells. | T1DM, T2DM, GDM, Other | Abbasi et al, 2016 |
ENPP7 | Converts sphingomyelin to ceramide and phosphocholine (PubMed:12885774, PubMed:12671034, PubMed:15205117, PubMed:28292932). Has also phospholipase C activity and can cleave phosphocholine from palmitoyl lyso-phosphatidylcholine (PubMed:12885774). Does not have nucleotide pyrophosphatase activity (PubMed:12885774). | – | No |
FAS | Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro). | T1DM, T2DM, Other | No |
GDF15 | Regulates food intake, energy expenditure and body weight in response to metabolic and toxin-induced stresses (PubMed:28953886, PubMed:28846097, PubMed:28846098, PubMed:28846099, PubMed:23468844, PubMed:29046435). Binds to its receptor, GFRAL, and activates GFRAL-expressing neurons localized in the area postrema and nucleus tractus solitarius of the brainstem (PubMed:28953886, PubMed:28846097, PubMed:28846098, PubMed:28846099). It then triggers the activation of neurons localized within the parabrachial nucleus and central amygdala, which contitutes part of the ‘emergency circuit’ that shapes feeding responses to stressful conditions (PubMed:28953886). On hepatocytes, inhibits growth hormone signaling (By similarity). | T1DM, T2DM, GDM, Other | No |
GGT1 | Cleaves the gamma-glutamyl bond of extracellular glutathione (gamma-Glu-Cys-Gly), glutathione conjugates, and other gamma-glutamyl compounds. The metabolism of glutathione releases free glutamate and the dipeptide cysteinyl-glycine, which is hydrolyzed to cysteine and glycine by dipeptidases. In the presence of high concentrations of dipeptides and some amino acids, can also catalyze a transpeptidation reaction, transferring the gamma-glutamyl moiety to an acceptor amino acid to form a new gamma-glutamyl compound. Initiates extracellular glutathione (GSH) breakdown, provides cells with a local cysteine supply and contributes to maintain intracellular GSH level. It is part of the cell antioxidant defense mechanism. Isoform 3 seems to be inactive. | T2DM | Abbasi et al, 2016 |
GPT | Catalyzes the reversible transamination between alanine and 2-oxoglutarate to form pyruvate and glutamate. Participates in cellular nitrogen metabolism and also in liver gluconeogenesis starting with precursors transported from skeletal muscles (By similarity). | T1DM, T2DM, GDM, Other | Abbasi et al, 2016 |
IL18R1 | Within the IL18 receptor complex, responsible for the binding of the proinflammatory cytokine IL18, but not IL1A nor IL1B (PubMed:8626725, PubMed:14528293, PubMed:25261253, PubMed:25500532). Involved in IL18-mediated IFNG synthesis from T-helper 1 (Th1) cells (PubMed:10653850). Contributes to IL18-induced cytokine production, either independently of SLC12A3, or as a complex with SLC12A3 (By similarity). | T2DM | No |
RTN4R | Receptor for RTN4, OMG and MAG (PubMed:12037567, PubMed:12068310, PubMed:12426574, PubMed:12089450, PubMed:16712417, PubMed:18411262, PubMed:12839991, PubMed:19052207). Functions as receptor for the sialylated gangliosides GT1b and GM1 (PubMed:18411262). Besides, functions as receptor for chondroitin sulfate proteoglycans (By similarity). Can also bind heparin (By similarity). Intracellular signaling cascades are triggered via the coreceptor NGFR (PubMed:12426574). Signaling mediates activation of Rho and downstream reorganization of the actin cytoskeleton (PubMed:16712417, PubMed:22325200). Mediates axonal growth inhibition (PubMed:12839991, PubMed:19052207, PubMed:28892071). Plays a role in regulating axon regeneration and neuronal plasticity in the adult central nervous system. Plays a role in postnatal brain development. Required for normal axon migration across the brain midline and normal formation of the corpus callosum. Protects motoneurons against apoptosis; protection against apoptosis is probably mediated via interaction with MAG. Acts in conjunction with RTN4 and LINGO1 in regulating neuronal precursor cell motility during cortical development. Like other family members, plays a role in restricting the number dendritic spines and the number of synapses that are formed during brain development (PubMed:22325200). | T2DM | No |
Table content:
Description (PHAROS): Full-text description of the role/function of the protein from PHAROS.
Diabetes associations (Open Targets): Gene-disease (diabetes mellitus) association through experiments or clinical trials. Direct associations with T1DM, T2DM and GDM are shown specifically, while all other diabetes mellitus diseases are included in “Other”.
Suggested biomarker: Known and suggested biomarkers from Abbasi et al, 2016, RHAPSODY partners (collected by the RHAPSODY biomarker taskforce) and based on PPI-network analysis of known biomarkers (in-house analysis).
“Description missing” indicates that no description was available for the target.
Individual volcano plots for each target with results from all RHAPSODY experiments plotted.
Empty plots indicates that the specific target were not measured in RHAPSODY experiments.
Experiment | Tissue | Comparison | log10 fold change | Adj. p-value | |
---|---|---|---|---|---|
Proteomics | |||||
GDF15 | WP3 GoDARTS + DCS | Blood | Cox model 1 | 0.424 | 0.030 |
CRELD1 | WP3 GoDARTS + DCS | Blood | Cox model 3 | 0.382 | 0.159 |
ENPP7 | WP3 GoDARTS + DCS | Blood | Cox model 3 | 0.357 | 0.159 |
FAS | WP3 GoDARTS + DCS | Blood | Cox model 3 | 0.315 | 0.159 |
IL18R1 | WP3 GoDARTS + DCS | Blood | Cox model 1 | 0.401 | 0.190 |
RTN4R | WP3 GoDARTS + DCS | Blood | Cox model 3 | 0.273 | 0.430 |
GPT | WP3 GoDARTS + DCS | Blood | Cox model 3 | 0.069 | 0.967 |
CRP | WP3 GoDARTS + DCS | Blood | Cox model 1 | -0.084 | 0.985 |
Transcriptomics | |||||
CRELD1 | IMIDIA | Islets | T2D vs ND | -0.450 | 1.73e-05 |
GPT | WP6 Mice | Liver | DBA2J D33 HF vs RC | -0.795 | 8.97e-05 |
FAS | IMIDIA | Islets | T2D vs ND | 0.514 | 1.42e-04 |
CRP | IMIDIA | Islets | T2D vs ND | 1.044 | 0.005 |
IL18R1 | WP5 | Islets LCM | T2D vs ND + Tubingen | 1.300 | 0.058 |
GDF15 | WP6 Mice | Liver | BALBC D05 HF vs RC | -2.114 | 0.077 |
RTN4R | WP6 Mice | Adipose tissue | BALBC D33 HF vs RC | 1.962 | 0.126 |
ENPP7 | IMIDIA | Islets | IGT vs ND | 0.149 | 0.363 |
GGT1 | IMIDIA | Islets | T2D vs ND | 0.331 | 0.375 |
Omics-specific volcano plots with the best result for each tissue based on lowest adjusted p-value. Best results (lowest adjusted p-value) for all targets is shown as background points.
The best results from each target is shown in a table format together with the experiment-specific information, including:
Significant results with an adjusted p-value <0.05 are shown in blue, while non-significant points are shown in gray.
Detected in blood | Adj. meta p-value | Rank | |
---|---|---|---|
ENPP7 | Yes | 1.42e-06 | 20 |
CRELD1 | Yes | 0.008 | 43 |
IL18R1 | Yes | 4.82e-08 | 94 |
RTN4R | Yes | 0.002 | 269 |
GDF15 | Yes | 2.22e-08 | 355 |
FAS | Yes | 3.76e-13 | 538 |
GGT1 | Yes | 0.371 | - |
GPT | Yes | 0.734 | - |
CRP | Yes | 0.986 | - |
The RHAPSODY meta rank is made to identify novel targets based on RHAPSODY experimental data. The rank is based on three steps:
Significant results with an adjusted meta p-value <0.05 are shown in blue, while non-significant points are shown in gray.
en-dash (-) indicates that no information was available for the target.
Omics type | log10 fold change | Adj. p-value | log10 fold change | Adj. p-value | |
---|---|---|---|---|---|
Adipose tissue | |||||
CRELD1 | Transcriptomics | – | – | -1.369 | 0.084 |
GPT | Transcriptomics | – | – | -1.371 | 0.120 |
IL18R1 | Transcriptomics | – | – | 1.371 | 0.124 |
RTN4R | Transcriptomics | – | – | 1.962 | 0.126 |
FAS | Transcriptomics | – | – | 0.399 | 0.136 |
ENPP7 | Transcriptomics | – | – | 2.279 | 0.654 |
Blood | |||||
GDF15 | Proteomics | 0.424 | 0.030 | – | – |
CRELD1 | Proteomics | 0.382 | 0.159 | – | – |
ENPP7 | Proteomics | 0.357 | 0.159 | – | – |
FAS | Proteomics | 0.315 | 0.159 | – | – |
IL18R1 | Proteomics | 0.401 | 0.190 | – | – |
RTN4R | Proteomics | 0.273 | 0.430 | – | – |
GPT | Proteomics | 0.069 | 0.967 | – | – |
CRP | Proteomics | -0.084 | 0.985 | – | – |
Islets | |||||
CRELD1 | Transcriptomics | -0.450 | 1.73e-05 | 0.206 | 0.212 |
FAS | Transcriptomics | 0.514 | 1.42e-04 | -0.418 | 0.402 |
CRP | Transcriptomics | 1.044 | 0.005 | -1.267 | 0.103 |
GDF15 | Transcriptomics | 0.333 | 0.149 | – | – |
IL18R1 | Transcriptomics | 0.238 | 0.241 | – | – |
ENPP7 | Transcriptomics | 0.149 | 0.363 | – | – |
GGT1 | Transcriptomics | 0.331 | 0.375 | – | – |
GPT | Transcriptomics | -0.067 | 0.440 | 0.417 | 0.152 |
Islets LCM | |||||
FAS | Transcriptomics | 1.092 | 0.010 | – | – |
IL18R1 | Transcriptomics | 1.300 | 0.058 | – | – |
CRP | Transcriptomics | 1.451 | 0.204 | – | – |
GDF15 | Transcriptomics | 0.683 | 0.394 | – | – |
GGT1 | Transcriptomics | 0.637 | 0.420 | – | – |
CRELD1 | Transcriptomics | -0.129 | 0.476 | – | – |
Liver | |||||
GPT | Transcriptomics | – | – | -0.795 | 8.97e-05 |
FAS | Transcriptomics | – | – | 0.737 | 0.006 |
CRELD1 | Transcriptomics | – | – | -0.532 | 0.026 |
GDF15 | Transcriptomics | – | – | -2.114 | 0.077 |
CRP | Transcriptomics | – | – | 0.357 | 0.114 |
Muscle | |||||
FAS | Transcriptomics | – | – | -1.179 | 0.003 |
GPT | Transcriptomics | – | – | 0.494 | 0.028 |
CRELD1 | Transcriptomics | – | – | -0.311 | 0.032 |
CRP | Transcriptomics | – | – | -2.606 | 0.516 |
Comparison of targets across tissues and species. The plot is made to enable direct comparison between targets. Dependent on the number of targets, the plot will give target comparisons horizontally (at 8 or fewer targets) or vertically (more than 8 targets).
Empty plots indicates that the specific target were not measured in RHAPSODY experiments.
Comparison of tissues across species for each target. The plot is made to enable direct comparison between tissues and species for each target.
Empty plots indicates that the specific target were not measured in RHAPSODY experiments.
The table summarizes the best results for each tissue and species based on adjusted p-value.
Significant results with an adjusted p-value <0.05 are shown in
blue,
while non-significant points are shown in gray.
en-dash (-) indicates that no information was available for the target.
Text mining results for target-disease (any) association based on in-house and PHAROS data.
To ease the comparison between the proteins, a geometric mean has been calculated for the five parameters. Geometric means can be calculated with the formula: \(GM = \sqrt[n]{x_{1} \cdot x_{2} \cdot ... \cdot x_{n}}\). Using the geometric mean instead of the arithmetic mean (normally known as mean or average) to summarize our data is beneficial for two reasons:
However, it is important to note that the geometric mean does not handle zeros and negative values. It is therefore not useful for all data types.
The in-house text-mining has been conducted in two modes for PubMed abstracts and full-text papers:
Using these text-mining results, we can compare the number of co-mentions associated with diabetes to all other diseases.
The plot is split into three panel (left-to-right):
The plot has been sorted according to highest full-text all diabetes co-mentions.
Open Targets association scores for the diabetes mellitus supergroup and selected subtypes.
Diabetes mellitus (EFO_0000400): Supergroup for all diabetes mellitus diseases.
T2DM (MONDO_0005148): Type 2 diabetes mellitus.
T1DM (MONDO_0005147): Type 1 diabetes mellitus.
GDM (EFO_0004593): Gestational diabetes mellitus.
Other diabetes mellitus subtypes: Any other diabetes mellitus subgroup than T2DM, T1DM and GDM, e.g., monogenic diabetes mellitus, prediabetes syndrome, and neonatal diabetes mellitus.
The Open Targets association score is a standardized measure reported
a value between 0 and 1. Here, 1 indicates a strong association, while 0
indicates that there is no known association. The score is calculated
with the formula \(s = F \cdot S \cdot
C\), where \(s\) is the score,
\(F\) is the frequency i.e. the
relative occurrence of a target-disease evidence, \(S\) is the severity i.e. the magnitude or
strength of the effect described by the evidence, and \(C\) is the confidence i.e. overall
confidence for the observation that generates the target-disease
evidence.
The targets are ranked according to the overall association score,
summarizing the seven association variables.
Source: Open
Targets Platform Documentation.
Target | Mean diabetes textmining % | Associated with diabetes | Suggested diabetes biomarkers | Potential interaction partners | High-confidence interaction partners | Total interaction partners |
---|---|---|---|---|---|---|
CRELD1 | - | 0 | 0 | 0 | 0 | 0 |
CRP | 12 | 47 | 11 | 55 | 13 | 68 |
ENPP7 | 15 | 9 | 0 | 20 | 0 | 20 |
FAS | 10 | 71 | 0 | 96 | 21 | 117 |
GDF15 | 10 | 45 | 2 | 67 | 2 | 69 |
GGT1 | 14 | 23 | 3 | 42 | 0 | 42 |
GPT | 12 | 48 | 1 | 75 | 0 | 75 |
IL18R1 | 13 | 8 | 1 | 8 | 4 | 12 |
RTN4R | 9 | 76 | 1 | 191 | 10 | 201 |
Protein-protein interaction networks based on physical links data from the STRING database. See Szklarczyk et al, 2018 for a description of the resource.
Network features:
Summary table:
In cases where none of the targets have any interaction partners (all or high-confident), the following error messages will be shown:
Unfortunately, no interactions were found for any of the selected targets.
Unfortunately, no high-confidence interactions were found for any of the selected targets.
Interaction partner | UniProt ID | Diabetes textmining % | Diabetes associations | Suggested diabetes biomarker | Experimental score | Database score | Textmining score | Combined score |
---|---|---|---|---|---|---|---|---|
CRP | ||||||||
RBP4 | P02753 | 38 | T1DM, T2DM, GDM, Other | Abbasi et al, 2016 | 0.00 | 0.00 | 0.19 | 0.19 |
FFAR2 | O15552 | 36 | T1DM, T2DM, Other | No | 0.27 | 0.00 | 0.05 | 0.28 |
APOB | P04114 | 34 | T1DM, T2DM, GDM, Other | Abbasi et al, 2016 | 0.00 | 0.00 | 0.35 | 0.34 |
ANGPTL4 | Q9BY76 | 27 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.21 | 0.21 |
OLR1 | P78380 | 26 | T2DM, GDM | RHAPSODY partner suggestion | 0.00 | 0.00 | 0.88 | 0.88 |
SELP | P16109 | 22 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.33 | 0.33 |
LEP | P41159 | 21 | T1DM, T2DM, GDM, Other | Abbasi et al, 2016 | 0.00 | 0.00 | 0.60 | 0.60 |
FCGR1B | Q92637 | 19 | – | No | 0.00 | 0.00 | 0.53 | 0.53 |
DDIT3 | P35638 | 18 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.41 | 0.41 |
SNRPN | P63162 | 16 | – | No | 0.00 | 0.00 | 0.25 | 0.25 |
TLR4 | O00206 | 16 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.15 | 0.15 |
SNRNP70 | P08621 | 15 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
CFHR5 | Q9BXR6 | 14 | – | No | 0.30 | 0.00 | 0.59 | 0.70 |
C1QC | P02747 | 14 | – | No | 0.00 | 0.60 | 0.26 | 0.69 |
APCS | P02743 | 14 | T1DM, GDM | No | 0.46 | 0.00 | 0.41 | 0.67 |
PTX3 | P26022 | 14 | T1DM, T2DM, GDM, Other | RHAPSODY partner suggestion | 0.30 | 0.00 | 0.00 | 0.30 |
C1QA | P02745 | 13 | – | No | 0.57 | 0.60 | 0.26 | 0.86 |
C1QB | P02746 | 13 | – | No | 0.00 | 0.60 | 0.00 | 0.60 |
CD14 | P08571 | 13 | T1DM | No | 0.00 | 0.00 | 0.25 | 0.25 |
FCN3 | O75636 | 13 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.16 | 0.16 |
CFHR3 | Q02985 | 12 | – | No | 0.42 | 0.00 | 0.00 | 0.42 |
LOX | P28300 | 12 | T1DM, T2DM, Other | No | 0.00 | 0.00 | 0.31 | 0.31 |
LAMA1 | P25391 | 12 | T2DM, Other | Network of genes in T2D loci (suggested candidate) | 0.29 | 0.00 | 0.00 | 0.28 |
GP1BA | P07359 | 12 | T2DM, Other | No | 0.00 | 0.00 | 0.25 | 0.24 |
CES1 | P23141 | 12 | T1DM, T2DM, Other | No | 0.06 | 0.00 | 0.21 | 0.22 |
PTPRS | Q13332 | 12 | T1DM | No | 0.19 | 0.00 | 0.00 | 0.19 |
PRSS23 | O95084 | 12 | T1DM | No | 0.18 | 0.00 | 0.00 | 0.18 |
CTSH | P09668 | 12 | T1DM, T2DM | No | 0.00 | 0.00 | 0.17 | 0.17 |
FCN2 | Q15485 | 11 | T1DM | Network expansion | 0.27 | 0.00 | 0.83 | 0.87 |
C4A | P0C0L4 | 11 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.72 | 0.72 |
C1GALT1 | Q9NS00 | 11 | Other | No | 0.26 | 0.00 | 0.00 | 0.26 |
CD53 | P19397 | 11 | – | No | 0.00 | 0.00 | 0.16 | 0.15 |
CFH | P08603 | 10 | T1DM, T2DM, GDM | Network expansion | 0.73 | 0.00 | 0.90 | 0.97 |
FCGR2A | P12318 | 10 | T1DM, T2DM, Other | No | 0.46 | 0.00 | 0.90 | 0.94 |
C3 | P01024 | 10 | T1DM, T2DM, GDM, Other | Abbasi et al, 2016 | 0.48 | 0.00 | 0.66 | 0.82 |
FCGR2B | P31994 | 10 | T2DM, Other | No | 0.00 | 0.00 | 0.75 | 0.75 |
FCGR3A | P08637 | 10 | T1DM | No | 0.00 | 0.00 | 0.27 | 0.27 |
CALR | P27797 | 10 | T1DM, T2DM | No | 0.00 | 0.00 | 0.23 | 0.23 |
UBR3 | Q6ZT12 | 10 | T1DM | No | 0.19 | 0.00 | 0.00 | 0.19 |
C4BPA | P04003 | 9 | – | No | 0.42 | 0.00 | 0.54 | 0.72 |
CFHR1 | Q03591 | 9 | T2DM | No | 0.30 | 0.00 | 0.41 | 0.56 |
FCN1 | O00602 | 8 | T1DM | No | 0.30 | 0.00 | 0.86 | 0.90 |
H2AC20 | Q16777 | 8 | – | No | 0.27 | 0.00 | 0.35 | 0.51 |
CFP | P27918 | 8 | T1DM, T2DM | Network expansion | 0.30 | 0.00 | 0.25 | 0.45 |
GMPPA | Q96IJ6 | 8 | Other | No | 0.28 | 0.00 | 0.00 | 0.28 |
CFI | P05156 | 8 | T1DM, T2DM, Other | No | 0.27 | 0.00 | 0.00 | 0.27 |
ST6GAL1 | P15907 | 8 | T1DM, T2DM | No | 0.00 | 0.00 | 0.27 | 0.27 |
CD209 | Q9NNX6 | 8 | T1DM, GDM | No | 0.00 | 0.00 | 0.26 | 0.26 |
CHST3 | Q7LGC8 | 8 | T1DM, T2DM | No | 0.18 | 0.00 | 0.00 | 0.18 |
CNTNAP3 | Q9BZ76 | 8 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
H1-0 | P07305 | 7 | Other | No | 0.00 | 0.00 | 0.29 | 0.29 |
KRT8 | P05787 | 7 | GDM | No | 0.00 | 0.00 | 0.28 | 0.28 |
H1-1 | Q02539 | 7 | T1DM | No | 0.27 | 0.00 | 0.00 | 0.27 |
STC2 | O76061 | 7 | T2DM, Other | No | 0.23 | 0.00 | 0.00 | 0.23 |
H2AW | Q7L7L0 | 7 | – | No | 0.00 | 0.00 | 0.21 | 0.21 |
MAPK8IP2 | Q13387 | 7 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
CFHR4 | Q92496 | 6 | – | No | 0.57 | 0.00 | 0.76 | 0.89 |
C1S | P09871 | 6 | – | No | 0.00 | 0.00 | 0.18 | 0.18 |
LGALS3BP | Q08380 | 5 | T1DM, T2DM | No | 0.00 | 0.00 | 0.21 | 0.21 |
ITM2B | Q9Y287 | 4 | T1DM, T2DM, Other | No | 0.18 | 0.00 | 0.00 | 0.17 |
CA11 | O75493 | - | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
FCGR1A | P12314 | - | – | No | 0.00 | 0.00 | 0.94 | 0.94 |
FCAR | P24071 | - | – | No | 0.00 | 0.00 | 0.44 | 0.44 |
C4B | P0C0L5 | - | T1DM | No | 0.00 | 0.00 | 0.31 | 0.31 |
C4B_2 | P0C0L5 | - | T1DM | No | 0.00 | 0.00 | 0.31 | 0.31 |
GP6 | Q9HCN6 | - | T1DM, T2DM | No | 0.00 | 0.00 | 0.27 | 0.27 |
S100A12 | P80511 | - | T2DM, Other | RHAPSODY partner suggestion | 0.00 | 0.00 | 0.18 | 0.18 |
ENPP7 | ||||||||
TTC17 | Q96AE7 | 29 | – | No | 0.13 | 0.00 | 0.26 | 0.33 |
ACER2 | Q5QJU3 | 22 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
ASAH2 | Q9NR71 | 19 | T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
CERS6 | Q6ZMG9 | 19 | T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
PIGF | Q07326 | 18 | – | No | 0.08 | 0.00 | 0.14 | 0.18 |
CERS4 | Q9HA82 | 17 | T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
SGPP1 | Q9BX95 | 17 | T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
CERS2 | Q96G23 | 17 | T1DM, T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
ACER1 | Q8TDN7 | 16 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
CERS3 | Q8IU89 | 16 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
PLPP3 | O14495 | 15 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
SGPP2 | Q8IWX5 | 14 | Other | No | 0.00 | 0.65 | 0.00 | 0.65 |
PLPP2 | O43688 | 14 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
ASAH1 | Q13510 | 13 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.65 | 0.00 | 0.65 |
GBA2 | Q9HCG7 | 11 | T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
DEGS2 | Q6QHC5 | 11 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
DEGS1 | O15121 | 10 | T1DM, T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
GBA | P04062 | 9 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
LRRC73 | Q5JTD7 | - | – | No | 0.26 | 0.00 | 0.00 | 0.26 |
CERS5 | Q8N5B7 | - | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
FAS | ||||||||
SFXN5 | Q8TD22 | 23 | – | No | 0.22 | 0.00 | 0.00 | 0.22 |
TNFRSF10A | O00220 | 22 | T1DM, T2DM, GDM | No | 0.00 | 0.60 | 0.42 | 0.76 |
GGCX | P38435 | 22 | – | No | 0.00 | 0.00 | 0.34 | 0.34 |
UFSP2 | Q9NUQ7 | 22 | – | No | 0.22 | 0.00 | 0.00 | 0.22 |
SPATA5L1 | Q9BVQ7 | 22 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
ACAD9 | Q9H845 | 21 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
NDUFAF1 | Q9Y375 | 20 | T1DM, T2DM, GDM, Other | No | 0.19 | 0.00 | 0.00 | 0.19 |
PEX1 | O43933 | 18 | Other | No | 0.27 | 0.00 | 0.00 | 0.27 |
MAP3K5 | Q99683 | 17 | T1DM, T2DM | No | 0.64 | 0.90 | 0.00 | 0.96 |
PEA15 | Q15121 | 17 | T2DM | No | 0.28 | 0.00 | 0.00 | 0.28 |
HNF4A | P41235 | 17 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.26 | 0.26 |
PDXDC1 | Q6P996 | 17 | T2DM | No | 0.22 | 0.00 | 0.00 | 0.22 |
CAV1 | Q03135 | 16 | T1DM, T2DM, GDM, Other | No | 0.48 | 0.00 | 0.46 | 0.71 |
HSPA5 | P11021 | 16 | T1DM, T2DM, GDM, Other | No | 0.27 | 0.00 | 0.00 | 0.27 |
MAPK8 | P45983 | 15 | T1DM, T2DM, GDM, Other | No | 0.64 | 0.00 | 0.00 | 0.64 |
TRAF2 | Q12933 | 15 | – | No | 0.00 | 0.60 | 0.00 | 0.60 |
LGALS3 | P17931 | 15 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.33 | 0.33 |
PIK3R1 | P27986 | 15 | T1DM, T2DM, GDM, Other | No | 0.27 | 0.00 | 0.00 | 0.27 |
ATG5 | Q9H1Y0 | 14 | T2DM, Other | No | 0.48 | 0.00 | 0.25 | 0.59 |
CD40 | P25942 | 14 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.53 | 0.53 |
TNFSF13 | O75888 | 14 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
LTA | P01374 | 14 | T1DM, T2DM, GDM, Other | No | 0.06 | 0.00 | 0.19 | 0.20 |
C1QC | P02747 | 14 | – | No | 0.00 | 0.00 | 0.18 | 0.18 |
TNFRSF1A | P19438 | 13 | T1DM, T2DM, GDM, Other | No | 0.29 | 0.00 | 0.40 | 0.55 |
WDR11 | Q9BZH6 | 13 | T2DM, Other | No | 0.42 | 0.00 | 0.00 | 0.42 |
MAP1LC3B | Q9GZQ8 | 13 | T2DM | No | 0.27 | 0.00 | 0.00 | 0.27 |
PSTPIP1 | O43586 | 13 | T2DM | No | 0.00 | 0.00 | 0.25 | 0.25 |
C1QA | P02745 | 13 | – | No | 0.00 | 0.00 | 0.18 | 0.18 |
FASLG | P48023 | 12 | T1DM, T2DM, Other | No | 0.65 | 0.90 | 0.90 | 1.00 |
FAF1 | Q9UNN5 | 12 | T2DM | No | 0.50 | 0.90 | 0.45 | 0.97 |
SQSTM1 | Q13501 | 12 | T1DM, T2DM, Other | No | 0.27 | 0.00 | 0.00 | 0.27 |
ANK3 | Q12955 | 12 | T1DM | No | 0.21 | 0.00 | 0.00 | 0.21 |
NRP1 | O14786 | 12 | T1DM, T2DM | No | 0.00 | 0.00 | 0.16 | 0.16 |
TNFRSF10B | O14763 | 11 | T1DM, T2DM | No | 0.29 | 0.60 | 0.00 | 0.70 |
PLCG1 | P19174 | 11 | T2DM | No | 0.27 | 0.00 | 0.61 | 0.70 |
RHOA | P61586 | 11 | T1DM, T2DM, Other | No | 0.65 | 0.00 | 0.00 | 0.65 |
HIPK3 | Q9H422 | 11 | T2DM, Other | No | 0.34 | 0.00 | 0.28 | 0.50 |
TRAF3 | Q13114 | 11 | T2DM | No | 0.27 | 0.00 | 0.00 | 0.27 |
CANX | P27824 | 11 | – | No | 0.00 | 0.00 | 0.25 | 0.25 |
ARF5 | P84085 | 11 | T2DM | No | 0.24 | 0.00 | 0.00 | 0.24 |
GPD1L | Q8N335 | 11 | – | No | 0.20 | 0.00 | 0.00 | 0.20 |
UNC5B | Q8IZJ1 | 11 | GDM | No | 0.00 | 0.00 | 0.18 | 0.18 |
RIPK1 | Q13546 | 10 | – | No | 0.44 | 0.90 | 0.47 | 0.97 |
CASP10 | Q92851 | 10 | – | No | 0.52 | 0.90 | 0.47 | 0.97 |
FAIM2 | Q9BWQ8 | 10 | T2DM, GDM | No | 0.27 | 0.90 | 0.00 | 0.92 |
PTPN13 | Q12923 | 10 | – | No | 0.48 | 0.00 | 0.41 | 0.68 |
TNFSF10 | P50591 | 10 | T1DM, T2DM | No | 0.00 | 0.60 | 0.00 | 0.60 |
FYN | P06241 | 10 | T2DM, GDM | No | 0.50 | 0.00 | 0.00 | 0.50 |
LCK | P06239 | 10 | T1DM | No | 0.48 | 0.00 | 0.00 | 0.48 |
HSPA8 | P11142 | 10 | – | No | 0.00 | 0.00 | 0.43 | 0.43 |
CTNNB1 | P35222 | 10 | T1DM, T2DM, GDM | No | 0.39 | 0.00 | 0.00 | 0.39 |
CASP3 | P42574 | 10 | T1DM, T2DM, GDM, Other | No | 0.06 | 0.36 | 0.00 | 0.37 |
TUBB4A | P04350 | 10 | Other | No | 0.28 | 0.00 | 0.00 | 0.28 |
HSPA4 | P34932 | 10 | – | No | 0.00 | 0.00 | 0.27 | 0.27 |
EIF2AK3 | Q9NZJ5 | 10 | T1DM, T2DM, GDM, Other | No | 0.27 | 0.00 | 0.00 | 0.27 |
FCGR2B | P31994 | 10 | T2DM, Other | No | 0.00 | 0.00 | 0.23 | 0.23 |
CDYL | Q9Y232 | 10 | – | No | 0.22 | 0.00 | 0.00 | 0.22 |
TUBB2B | Q9BVA1 | 10 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
UGDH | O60701 | 10 | – | No | 0.19 | 0.00 | 0.00 | 0.19 |
CFLAR | O15519 | 9 | T2DM | No | 0.49 | 0.90 | 0.45 | 0.97 |
SRC | P12931 | 9 | T1DM, T2DM | No | 0.48 | 0.90 | 0.20 | 0.95 |
BTK | Q06187 | 9 | – | No | 0.00 | 0.90 | 0.07 | 0.90 |
SYK | P43405 | 9 | Other | No | 0.00 | 0.90 | 0.00 | 0.90 |
SUMO1 | P63165 | 9 | T1DM, T2DM | No | 0.48 | 0.00 | 0.61 | 0.79 |
BID | P55957 | 9 | T1DM | No | 0.65 | 0.00 | 0.00 | 0.65 |
RAP1A | P62834 | 9 | T2DM, GDM | No | 0.55 | 0.00 | 0.00 | 0.55 |
UBE2I | P63279 | 9 | T2DM | No | 0.50 | 0.00 | 0.00 | 0.50 |
HIPK2 | Q9H2X6 | 9 | – | No | 0.10 | 0.00 | 0.41 | 0.45 |
TRIP6 | Q15654 | 9 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
CD44 | P16070 | 9 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.26 | 0.25 |
TUBB2A | Q13885 | 9 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
CASP8 | Q14790 | 8 | T1DM, T2DM | No | 0.53 | 0.90 | 0.94 | 1.00 |
FADD | Q13158 | 8 | T1DM | No | 0.95 | 0.90 | 0.91 | 1.00 |
YES1 | P07947 | 8 | – | No | 0.48 | 0.00 | 0.00 | 0.48 |
BMP1 | P13497 | 8 | – | No | 0.00 | 0.00 | 0.29 | 0.29 |
APAF1 | O14727 | 8 | – | No | 0.25 | 0.00 | 0.00 | 0.24 |
RUFY1 | Q96T51 | 8 | T2DM | No | 0.23 | 0.00 | 0.00 | 0.23 |
EGFR | P00533 | 7 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.75 | 0.75 |
EZR | P15311 | 7 | T1DM | No | 0.47 | 0.00 | 0.16 | 0.54 |
FEM1B | Q9UK73 | 7 | T1DM, T2DM, Other | No | 0.21 | 0.00 | 0.28 | 0.41 |
PML | P29590 | 7 | T1DM, T2DM | No | 0.34 | 0.00 | 0.00 | 0.34 |
MSN | P26038 | 7 | T2DM | No | 0.30 | 0.00 | 0.00 | 0.30 |
ARHGDIA | P52565 | 7 | T1DM, Other | No | 0.29 | 0.00 | 0.00 | 0.29 |
RARA | P10276 | 7 | T2DM | No | 0.27 | 0.00 | 0.00 | 0.27 |
IFNB1 | P01574 | 7 | T1DM, T2DM, Other | No | 0.00 | 0.00 | 0.26 | 0.26 |
RHOBTB3 | O94955 | 7 | – | No | 0.22 | 0.00 | 0.00 | 0.22 |
LYN | P07948 | 7 | T1DM, T2DM, Other | No | 0.00 | 0.00 | 0.22 | 0.22 |
UBA7 | P41226 | 7 | T2DM | No | 0.21 | 0.00 | 0.00 | 0.21 |
FAF2 | Q96CS3 | 7 | – | No | 0.20 | 0.00 | 0.00 | 0.20 |
KRIT1 | O00522 | 6 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
TUBB3 | Q13509 | 6 | – | No | 0.24 | 0.00 | 0.00 | 0.24 |
DPH1 | Q9BZG8 | 6 | – | No | 0.23 | 0.00 | 0.00 | 0.23 |
RDX | P35241 | 6 | T1DM, T2DM | No | 0.06 | 0.00 | 0.20 | 0.21 |
FBF1 | Q8TES7 | 6 | Other | No | 0.19 | 0.00 | 0.00 | 0.19 |
C17orf75 | Q9HAS0 | 5 | – | No | 0.63 | 0.00 | 0.00 | 0.63 |
PLK3 | Q9H4B4 | 5 | – | No | 0.00 | 0.00 | 0.40 | 0.40 |
PRAM1 | Q96QH2 | 5 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
PDCD6 | O75340 | 5 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
PLK1 | P53350 | 5 | T2DM, GDM | No | 0.00 | 0.00 | 0.20 | 0.20 |
MAP1S | Q66K74 | 5 | – | No | 0.19 | 0.00 | 0.00 | 0.19 |
INPP5D | Q92835 | 4 | T1DM, T2DM | No | 0.27 | 0.00 | 0.25 | 0.43 |
TP63 | Q9H3D4 | 4 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
EEF1AKNMT | Q8N6R0 | 4 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
INTS2 | Q9H0H0 | 4 | – | No | 0.19 | 0.00 | 0.00 | 0.19 |
BABAM2 | Q9NXR7 | 3 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
CTU2 | Q2VPK5 | 3 | – | No | 0.24 | 0.00 | 0.00 | 0.24 |
FAM91A1 | Q658Y4 | - | – | No | 0.41 | 0.00 | 0.00 | 0.41 |
FAM118B | Q9BPY3 | - | – | No | 0.23 | 0.00 | 0.00 | 0.23 |
TIMM29 | Q9BSF4 | - | – | No | 0.23 | 0.00 | 0.00 | 0.23 |
DAXX | Q9UER7 | - | T1DM | No | 0.66 | 0.90 | 0.39 | 0.98 |
TRADD | Q15628 | - | – | No | 0.46 | 0.90 | 0.28 | 0.96 |
CALM1 | P0DP23 | - | T1DM, GDM | No | 0.80 | 0.00 | 0.00 | 0.80 |
PRKCA | P17252 | - | T1DM, T2DM | No | 0.55 | 0.00 | 0.00 | 0.55 |
TNF | P01375 | - | T1DM, T2DM, GDM, Other | No | 0.28 | 0.00 | 0.19 | 0.39 |
ABHD11 | Q8NFV4 | - | Other | No | 0.39 | 0.00 | 0.00 | 0.39 |
CASP8AP2 | Q9UKL3 | - | – | No | 0.34 | 0.00 | 0.00 | 0.34 |
CHD1L | Q86WJ1 | - | T2DM | No | 0.21 | 0.00 | 0.00 | 0.21 |
GDF15 | ||||||||
INSR | P06213 | 27 | T1DM, T2DM, GDM, Other | No | 0.15 | 0.00 | 0.08 | 0.18 |
ERN1 | O75460 | 26 | T1DM, T2DM, GDM, Other | No | 0.15 | 0.00 | 0.07 | 0.17 |
PRKCZ | Q05513 | 23 | T2DM, GDM | No | 0.15 | 0.00 | 0.05 | 0.16 |
GSK3A | P49840 | 22 | T1DM, T2DM, GDM, Other | No | 0.15 | 0.00 | 0.06 | 0.16 |
IGF1R | P08069 | 17 | T1DM, T2DM, GDM, Other | RHAPSODY partner suggestion | 0.15 | 0.00 | 0.08 | 0.18 |
IRAK3 | Q9Y616 | 16 | T1DM, T2DM | No | 0.15 | 0.00 | 0.05 | 0.16 |
GSK3B | P49841 | 15 | T1DM, T2DM, GDM, Other | No | 0.15 | 0.00 | 0.08 | 0.18 |
STAT5A | P42229 | 14 | T1DM, T2DM, GDM | No | 0.25 | 0.00 | 0.00 | 0.25 |
ACVR1C | Q8NER5 | 14 | T2DM | No | 0.15 | 0.00 | 0.05 | 0.16 |
PRKCI | P41743 | 14 | – | No | 0.15 | 0.00 | 0.05 | 0.16 |
SETD4 | Q9NVD3 | 13 | Other | No | 0.26 | 0.00 | 0.00 | 0.26 |
MAP3K11 | Q16584 | 13 | – | No | 0.15 | 0.00 | 0.08 | 0.18 |
IRAK4 | Q9NWZ3 | 13 | T2DM | No | 0.15 | 0.00 | 0.05 | 0.16 |
ACVRL1 | P37023 | 12 | – | No | 0.15 | 0.00 | 0.30 | 0.38 |
CDC42BPG | Q6DT37 | 12 | – | No | 0.15 | 0.00 | 0.14 | 0.23 |
CDC42BPB | Q9Y5S2 | 12 | – | No | 0.15 | 0.00 | 0.08 | 0.18 |
MAP3K21 | Q5TCX8 | 12 | – | No | 0.15 | 0.00 | 0.08 | 0.18 |
ROCK1 | Q13464 | 12 | T1DM, T2DM | No | 0.15 | 0.00 | 0.08 | 0.18 |
CCN3 | P48745 | 12 | T2DM | Network expansion | 0.00 | 0.00 | 0.17 | 0.17 |
ACVR2A | P27037 | 12 | – | No | 0.15 | 0.00 | 0.06 | 0.16 |
IRAK1 | P51617 | 12 | T1DM, T2DM | No | 0.15 | 0.00 | 0.05 | 0.16 |
MAP3K9 | P80192 | 11 | – | No | 0.15 | 0.00 | 0.11 | 0.21 |
ROCK2 | O75116 | 11 | T1DM, T2DM | No | 0.15 | 0.00 | 0.08 | 0.18 |
MAP3K10 | Q02779 | 11 | – | No | 0.15 | 0.00 | 0.08 | 0.18 |
COL12A1 | Q99715 | 11 | – | No | 0.08 | 0.00 | 0.14 | 0.17 |
RIPK3 | Q9Y572 | 11 | T1DM, T2DM | No | 0.15 | 0.00 | 0.07 | 0.17 |
ACVR1B | P36896 | 11 | – | No | 0.15 | 0.00 | 0.05 | 0.16 |
LIMK2 | P53671 | 11 | – | No | 0.15 | 0.00 | 0.05 | 0.16 |
PASK | Q96RG2 | 11 | T2DM, Other | No | 0.15 | 0.00 | 0.04 | 0.15 |
BMPR1A | P36894 | 10 | T2DM | No | 0.15 | 0.00 | 0.10 | 0.20 |
AXL | P30530 | 10 | T1DM, T2DM | No | 0.15 | 0.00 | 0.08 | 0.18 |
IRAK2 | O43187 | 10 | T2DM | No | 0.15 | 0.00 | 0.05 | 0.16 |
NTRK1 | P04629 | 10 | T1DM, T2DM, GDM, Other | No | 0.15 | 0.00 | 0.05 | 0.16 |
ERN2 | Q76MJ5 | 10 | – | No | 0.15 | 0.00 | 0.06 | 0.16 |
TGFBR2 | P37173 | 9 | T1DM, T2DM | No | 0.15 | 0.00 | 0.42 | 0.49 |
NTRK2 | Q16620 | 9 | T1DM, T2DM, Other | No | 0.15 | 0.00 | 0.08 | 0.18 |
RIPK2 | O43353 | 9 | T2DM | No | 0.15 | 0.00 | 0.08 | 0.18 |
BMPR1B | O00238 | 9 | T2DM | No | 0.15 | 0.00 | 0.07 | 0.17 |
GDNF | P39905 | 9 | T1DM, T2DM, Other | No | 0.00 | 0.00 | 0.16 | 0.16 |
PTK7 | Q13308 | 9 | – | No | 0.15 | 0.00 | 0.04 | 0.15 |
LRRK2 | Q5S007 | 9 | T1DM, T2DM, Other | No | 0.15 | 0.00 | 0.05 | 0.15 |
SAE1 | Q9UBE0 | 8 | T2DM | No | 0.21 | 0.00 | 0.00 | 0.21 |
CDC42BPA | Q5VT25 | 8 | – | No | 0.15 | 0.00 | 0.08 | 0.18 |
NTRK3 | Q16288 | 8 | – | No | 0.15 | 0.00 | 0.08 | 0.18 |
PTK6 | Q13882 | 8 | – | No | 0.15 | 0.00 | 0.06 | 0.17 |
MET | P08581 | 8 | T1DM, T2DM, GDM, Other | No | 0.15 | 0.00 | 0.05 | 0.16 |
MERTK | Q12866 | 8 | T2DM, Other | No | 0.15 | 0.00 | 0.06 | 0.16 |
TWSG1 | Q9GZX9 | 7 | T1DM | No | 0.10 | 0.00 | 0.65 | 0.67 |
VIM | P08670 | 7 | T1DM, T2DM, Other | No | 0.14 | 0.00 | 0.27 | 0.34 |
GFRA1 | P56159 | 7 | – | No | 0.00 | 0.00 | 0.27 | 0.27 |
ABL2 | P42684 | 7 | T2DM | No | 0.15 | 0.00 | 0.08 | 0.18 |
ALK | Q9UM73 | 7 | T1DM, Other | No | 0.15 | 0.00 | 0.06 | 0.17 |
MDM2 | Q00987 | 6 | T1DM, T2DM | No | 0.00 | 0.00 | 0.25 | 0.25 |
NUP58 | Q9BVL2 | 6 | T1DM | No | 0.21 | 0.00 | 0.00 | 0.21 |
NLGN3 | Q9NZ94 | 6 | T2DM | No | 0.19 | 0.00 | 0.00 | 0.19 |
FES | P07332 | 6 | – | No | 0.15 | 0.00 | 0.05 | 0.16 |
PKDCC | Q504Y2 | 6 | – | No | 0.15 | 0.00 | 0.05 | 0.16 |
RET | P07949 | 5 | T1DM, T2DM, Other | No | 0.80 | 0.00 | 0.27 | 0.85 |
ENG | P17813 | 5 | T1DM, T2DM, Other | No | 0.27 | 0.00 | 0.00 | 0.27 |
CIT | O14578 | 5 | – | No | 0.15 | 0.00 | 0.08 | 0.18 |
ROS1 | P08922 | 5 | T2DM | No | 0.15 | 0.00 | 0.05 | 0.16 |
GFRAL | Q6UXV0 | 4 | T2DM | No | 0.80 | 0.00 | 0.90 | 0.98 |
MDFI | Q99750 | 4 | – | No | 0.28 | 0.00 | 0.00 | 0.28 |
CBX3 | Q13185 | 4 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
INSRR | P14616 | 4 | T2DM | No | 0.15 | 0.00 | 0.08 | 0.18 |
MST1R | Q04912 | 3 | T2DM | No | 0.15 | 0.00 | 0.05 | 0.16 |
FER | P16591 | 3 | Other | No | 0.15 | 0.00 | 0.05 | 0.16 |
CCN2 | P29279 | - | T1DM, T2DM, Other | No | 0.00 | 0.00 | 0.28 | 0.28 |
LIMK1 | P53667 | - | – | No | 0.15 | 0.00 | 0.05 | 0.16 |
GGT1 | ||||||||
DPP4 | P27487 | 38 | T1DM, T2DM, GDM, Other | Abbasi et al, 2016 | 0.00 | 0.00 | 0.23 | 0.23 |
NAMPT | P43490 | 35 | T1DM, T2DM, GDM, Other | Network expansion | 0.19 | 0.00 | 0.00 | 0.19 |
APOB | P04114 | 34 | T1DM, T2DM, GDM, Other | Abbasi et al, 2016 | 0.00 | 0.00 | 0.27 | 0.27 |
GPX1 | P07203 | 22 | T1DM, T2DM, Other | No | 0.00 | 0.65 | 0.00 | 0.65 |
GPX8 | Q8TED1 | 19 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
GPX3 | P22352 | 19 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.65 | 0.00 | 0.65 |
GSTO2 | Q9H4Y5 | 18 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
GSTA4 | O15217 | 17 | T2DM | No | 0.00 | 0.65 | 0.06 | 0.66 |
HNF4A | P41235 | 17 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.25 | 0.25 |
GGT2 | P36268 | 16 | – | No | 0.54 | 0.00 | 0.00 | 0.54 |
CYP2E1 | P05181 | 16 | T1DM, T2DM | No | 0.00 | 0.00 | 0.26 | 0.26 |
GSTM5 | P46439 | 15 | T2DM | No | 0.00 | 0.65 | 0.14 | 0.69 |
GPX2 | P18283 | 15 | T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
GSTM4 | Q03013 | 14 | – | No | 0.00 | 0.65 | 0.16 | 0.69 |
GSTM1 | P09488 | 14 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.65 | 0.14 | 0.69 |
GPX7 | Q96SL4 | 14 | T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
GPX6 | P59796 | 14 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
GSTT2B | P0CG30 | 14 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
GSTA1 | P08263 | 13 | T1DM, T2DM, Other | No | 0.00 | 0.65 | 0.06 | 0.66 |
GGT7 | Q9UJ14 | 13 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
GPX5 | O75715 | 13 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
SMARCAD1 | Q9H4L7 | 13 | T2DM | No | 0.16 | 0.00 | 0.00 | 0.16 |
GSTM2 | P28161 | 12 | T2DM | No | 0.00 | 0.65 | 0.16 | 0.69 |
GSTA2 | P09210 | 12 | – | No | 0.00 | 0.65 | 0.06 | 0.66 |
GSTA3 | Q16772 | 12 | T2DM | No | 0.00 | 0.65 | 0.06 | 0.66 |
MGST3 | O14880 | 12 | T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
GSTM3 | P21266 | 11 | – | No | 0.00 | 0.65 | 0.12 | 0.68 |
GSTA5 | Q7RTV2 | 11 | – | No | 0.00 | 0.65 | 0.06 | 0.66 |
MGST1 | P10620 | 11 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
GYG1 | P46976 | 11 | T2DM | No | 0.27 | 0.00 | 0.00 | 0.27 |
CD53 | P19397 | 11 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
CANX | P27824 | 11 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
GGT6 | Q6P531 | 10 | – | No | 0.00 | 0.65 | 0.00 | 0.65 |
MGST2 | Q99735 | 10 | T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
HPGDS | O60760 | 10 | T1DM, T2DM | No | 0.00 | 0.65 | 0.05 | 0.65 |
DNPEP | Q9ULA0 | 10 | – | No | 0.00 | 0.00 | 0.16 | 0.16 |
GSTP1 | P09211 | 9 | T2DM, GDM, Other | No | 0.00 | 0.65 | 0.06 | 0.66 |
CD81 | P60033 | 9 | – | No | 0.29 | 0.00 | 0.00 | 0.29 |
GSTO1 | P78417 | 8 | T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
NUBPL | Q8TB37 | 8 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
CD82 | P27701 | 7 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
GGT5 | P36269 | 5 | T2DM | No | 0.00 | 0.65 | 0.00 | 0.65 |
GPT | ||||||||
PRKAA2 | P54646 | 33 | T1DM, T2DM, GDM, Other | No | 0.22 | 0.00 | 0.00 | 0.22 |
PRKAG1 | P54619 | 30 | Other | No | 0.24 | 0.00 | 0.00 | 0.24 |
AGXT2 | Q9BYV1 | 21 | T2DM | No | 0.34 | 0.00 | 0.00 | 0.34 |
H6PD | O95479 | 21 | T1DM, T2DM, Other | No | 0.21 | 0.00 | 0.00 | 0.21 |
ALDH6A1 | Q02252 | 20 | T1DM | No | 0.33 | 0.00 | 0.00 | 0.33 |
PRKAG2 | Q9UGJ0 | 20 | T2DM, Other | No | 0.24 | 0.00 | 0.00 | 0.24 |
BDH2 | Q9BUT1 | 20 | T2DM | No | 0.16 | 0.00 | 0.00 | 0.16 |
NPEPL1 | Q8NDH3 | 19 | – | No | 0.26 | 0.00 | 0.00 | 0.26 |
ALDH9A1 | P49189 | 19 | – | No | 0.20 | 0.00 | 0.00 | 0.20 |
ALDH16A1 | Q8IZ83 | 18 | – | No | 0.20 | 0.00 | 0.00 | 0.20 |
DHRS1 | Q96LJ7 | 18 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
HSD17B14 | Q9BPX1 | 17 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
TKTL2 | Q9H0I9 | 15 | – | No | 0.28 | 0.00 | 0.00 | 0.28 |
TKT | P29401 | 15 | T1DM, T2DM, GDM, Other | No | 0.28 | 0.00 | 0.00 | 0.28 |
CAT | P04040 | 15 | T1DM, T2DM, GDM, Other | No | 0.27 | 0.00 | 0.00 | 0.27 |
ALDH2 | P05091 | 15 | T1DM, T2DM | No | 0.26 | 0.00 | 0.00 | 0.26 |
SASS6 | Q6UVJ0 | 15 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
CES3 | Q6UWW8 | 15 | T2DM | No | 0.15 | 0.00 | 0.00 | 0.15 |
ALDH8A1 | Q9H2A2 | 14 | – | No | 0.20 | 0.00 | 0.00 | 0.20 |
BCAT2 | O15382 | 14 | T1DM, T2DM, Other | No | 0.00 | 0.00 | 0.20 | 0.20 |
DECR1 | Q16698 | 14 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
CES2 | O00748 | 13 | Other | No | 0.23 | 0.00 | 0.00 | 0.23 |
HSPD1 | P10809 | 13 | T1DM, T2DM, Other | No | 0.17 | 0.00 | 0.00 | 0.17 |
DECR2 | Q9NUI1 | 13 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
CEL | P19835 | 13 | T1DM, T2DM, Other | No | 0.15 | 0.00 | 0.00 | 0.15 |
ACO1 | P21399 | 13 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
ACO2 | Q99798 | 12 | T1DM, T2DM | No | 0.34 | 0.00 | 0.00 | 0.34 |
PEPD | P12955 | 12 | T2DM, GDM | No | 0.34 | 0.00 | 0.00 | 0.34 |
FH | P07954 | 12 | T1DM, T2DM | No | 0.34 | 0.00 | 0.00 | 0.34 |
LAP3 | P28838 | 12 | T1DM, T2DM | No | 0.26 | 0.00 | 0.00 | 0.26 |
ALDH1A2 | O94788 | 12 | T2DM | No | 0.26 | 0.00 | 0.00 | 0.26 |
TKTL1 | P51854 | 12 | – | No | 0.26 | 0.00 | 0.00 | 0.26 |
CES1 | P23141 | 12 | T1DM, T2DM, Other | No | 0.23 | 0.00 | 0.00 | 0.23 |
BCAT1 | P54687 | 12 | T1DM, T2DM | No | 0.00 | 0.00 | 0.20 | 0.20 |
HSDL2 | Q6YN16 | 12 | T1DM | No | 0.16 | 0.00 | 0.00 | 0.16 |
ALDH7A1 | P49419 | 11 | T1DM, T2DM | No | 0.34 | 0.00 | 0.00 | 0.34 |
PHYHD1 | Q5SRE7 | 11 | – | Network expansion | 0.26 | 0.00 | 0.00 | 0.26 |
SI | P14410 | 11 | T2DM | No | 0.25 | 0.00 | 0.00 | 0.25 |
DHRS4 | Q9BTZ2 | 11 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
CTBP2 | P56545 | 11 | T1DM, GDM | No | 0.15 | 0.00 | 0.00 | 0.15 |
IREB2 | P48200 | 11 | Other | No | 0.15 | 0.00 | 0.00 | 0.15 |
TALDO1 | P37837 | 10 | – | No | 0.34 | 0.00 | 0.00 | 0.34 |
ALDH1B1 | P30837 | 10 | Other | No | 0.26 | 0.00 | 0.00 | 0.26 |
GAA | P10253 | 10 | T1DM, T2DM, Other | No | 0.25 | 0.00 | 0.00 | 0.25 |
G6PD | P11413 | 10 | T1DM | No | 0.24 | 0.00 | 0.00 | 0.24 |
ALDH1A3 | P47895 | 10 | T2DM | No | 0.20 | 0.00 | 0.00 | 0.20 |
TPI1 | P60174 | 9 | T1DM, T2DM, Other | No | 0.34 | 0.00 | 0.00 | 0.34 |
GBA | P04062 | 9 | – | No | 0.19 | 0.00 | 0.00 | 0.19 |
ATP6V1D | Q9Y5K8 | 9 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
CES4A | Q5XG92 | 9 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
ALDH1A1 | P00352 | 8 | T2DM | No | 0.26 | 0.00 | 0.00 | 0.26 |
DHRS2 | Q13268 | 8 | T2DM | No | 0.16 | 0.00 | 0.00 | 0.16 |
CTBP1 | Q13363 | 8 | T2DM | No | 0.15 | 0.00 | 0.00 | 0.15 |
FOLR1 | P15328 | 7 | – | No | 0.00 | 0.00 | 0.47 | 0.47 |
PHYH | O14832 | 7 | T2DM | No | 0.34 | 0.00 | 0.00 | 0.34 |
ABAT | P80404 | 7 | T1DM | No | 0.34 | 0.00 | 0.00 | 0.34 |
PHGDH | O43175 | 7 | T1DM, T2DM | No | 0.34 | 0.00 | 0.00 | 0.34 |
CAPN1 | P07384 | 7 | T2DM | No | 0.27 | 0.00 | 0.00 | 0.27 |
MGAM | O43451 | 7 | T1DM, T2DM, GDM | No | 0.25 | 0.00 | 0.00 | 0.25 |
MYORG | Q6NSJ0 | 7 | – | No | 0.24 | 0.00 | 0.00 | 0.24 |
DHRS4L2 | Q6PKH6 | 7 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
AP2M1 | Q96CW1 | 7 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
NLGN2 | Q8NFZ4 | 7 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
NLGN1 | Q8N2Q7 | 7 | T2DM | No | 0.15 | 0.00 | 0.00 | 0.15 |
NLGN4X | Q8N0W4 | 7 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
CFL1 | P23528 | 6 | T1DM, T2DM | No | 0.27 | 0.00 | 0.00 | 0.27 |
MDM2 | Q00987 | 6 | T1DM, T2DM | No | 0.00 | 0.00 | 0.24 | 0.24 |
HLTF | Q14527 | 6 | T1DM | No | 0.16 | 0.00 | 0.00 | 0.16 |
NLGN3 | Q9NZ94 | 6 | T2DM | No | 0.15 | 0.00 | 0.00 | 0.15 |
DCAF7 | P61962 | 5 | T2DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
CES5A | Q6NT32 | 4 | – | No | 0.23 | 0.00 | 0.00 | 0.23 |
RALA | P11233 | 4 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
PECR | Q9BY49 | 3 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
MGAM2 | Q2M2H8 | - | T2DM | No | 0.25 | 0.00 | 0.00 | 0.25 |
PRKAB2 | O43741 | - | T2DM, Other | No | 0.22 | 0.00 | 0.00 | 0.22 |
IL18R1 | ||||||||
SCT | P09683 | 21 | T1DM, T2DM | No | 0.00 | 0.00 | 0.28 | 0.28 |
IL18 | Q14116 | 19 | T1DM, T2DM, GDM, Other | Abbasi et al, 2016 | 0.93 | 0.90 | 0.91 | 1.00 |
IL33 | O95760 | 15 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.54 | 0.54 |
IL37 | Q9NZH6 | 13 | T1DM, T2DM, GDM | No | 0.28 | 0.60 | 0.78 | 0.93 |
IL18RAP | O95256 | 12 | T1DM | No | 0.80 | 0.90 | 0.91 | 1.00 |
SIGIRR | Q6IA17 | 12 | – | No | 0.00 | 0.60 | 0.60 | 0.84 |
IRAK1 | P51617 | 12 | T1DM, T2DM | No | 0.05 | 0.00 | 0.19 | 0.19 |
SLC12A3 | P55017 | 12 | T1DM, T2DM | No | 0.18 | 0.00 | 0.00 | 0.18 |
TICAM2 | Q86XR7 | 11 | – | No | 0.00 | 0.00 | 0.21 | 0.21 |
DNMT3A | Q9Y6K1 | 10 | T1DM, T2DM, GDM | No | 0.00 | 0.00 | 0.43 | 0.43 |
IL1RAPL1 | Q9NZN1 | 8 | – | No | 0.00 | 0.00 | 0.56 | 0.56 |
RTN4R | ||||||||
BUD13 | Q9BRD0 | 31 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
CAB39 | Q9Y376 | 23 | – | No | 0.17 | 0.00 | 0.11 | 0.23 |
CISD3 | P0C7P0 | 23 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
SORT1 | Q99523 | 20 | T2DM, Other | No | 0.00 | 0.00 | 0.38 | 0.38 |
MRPS16 | Q9Y3D3 | 20 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
SLC25A10 | Q9UBX3 | 20 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
RPL3L | Q92901 | 20 | – | No | 0.17 | 0.00 | 0.00 | 0.16 |
SNAPC4 | Q5SXM2 | 19 | T1DM, T2DM | No | 0.16 | 0.00 | 0.00 | 0.16 |
PTPRQ | Q9UMZ3 | 18 | – | No | 0.27 | 0.00 | 0.00 | 0.27 |
MRPL33 | O75394 | 18 | T1DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
CTH | P32929 | 17 | T1DM, T2DM | No | 0.00 | 0.00 | 0.25 | 0.25 |
TNFRSF1B | P20333 | 17 | T1DM, T2DM, GDM | Abbasi et al, 2016 | 0.00 | 0.00 | 0.21 | 0.21 |
PTPRA | P18433 | 17 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
STK25 | O00506 | 17 | T1DM, T2DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
CAB39L | Q9H9S4 | 16 | – | No | 0.17 | 0.00 | 0.11 | 0.23 |
PTPRE | P23469 | 16 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
NWD1 | Q149M9 | 16 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
NRXN3 | Q9Y4C0 | 16 | T2DM | No | 0.18 | 0.00 | 0.00 | 0.18 |
FXN | Q16595 | 16 | T2DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
MRPS5 | P82675 | 16 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
MRPL12 | P52815 | 16 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
SNRPN | P63162 | 16 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
SUOX | P51687 | 15 | T1DM, T2DM | No | 0.19 | 0.00 | 0.00 | 0.19 |
PTPRT | O14522 | 15 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
USHBP1 | Q8N6Y0 | 15 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
MRPL21 | Q7Z2W9 | 15 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
MRPL4 | Q9BYD3 | 15 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
MT-ND1 | P03886 | 14 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.61 | 0.61 |
LTA | P01374 | 14 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.44 | 0.44 |
ZMAT5 | Q9UDW3 | 14 | T2DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
S1PR2 | O95136 | 13 | T2DM | No | 0.00 | 0.00 | 0.37 | 0.37 |
KDR | P35968 | 13 | T1DM, T2DM, GDM | No | 0.08 | 0.00 | 0.26 | 0.29 |
LY86 | O95711 | 13 | Other | No | 0.20 | 0.00 | 0.00 | 0.20 |
PTPRD | P23468 | 13 | T2DM, GDM | No | 0.18 | 0.00 | 0.00 | 0.18 |
SNRPB2 | P08579 | 13 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
SART1 | O43290 | 13 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
PPP1CC | P36873 | 13 | – | No | 0.16 | 0.00 | 0.05 | 0.16 |
PPP1CB | P62140 | 13 | T1DM, T2DM | No | 0.16 | 0.00 | 0.05 | 0.16 |
PPP3CB | P16298 | 13 | – | No | 0.16 | 0.00 | 0.05 | 0.16 |
RNPC3 | Q96LT9 | 12 | T2DM | No | 0.18 | 0.00 | 0.00 | 0.18 |
PTPRS | Q13332 | 12 | T1DM | No | 0.18 | 0.00 | 0.00 | 0.18 |
STK24 | Q9Y6E0 | 12 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
LSM8 | O95777 | 12 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
PPP3CC | P48454 | 12 | – | No | 0.16 | 0.00 | 0.05 | 0.16 |
PPP2CA | P67775 | 12 | T2DM | No | 0.16 | 0.00 | 0.05 | 0.16 |
SNRPD1 | P62314 | 12 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
MSRB3 | Q8IXL7 | 12 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
MSRB2 | Q9Y3D2 | 12 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
ACTB | P60709 | 11 | T1DM, T2DM, GDM, Other | No | 0.10 | 0.00 | 0.31 | 0.35 |
ITGB1 | P05556 | 11 | T1DM, T2DM, GDM | No | 0.04 | 0.00 | 0.23 | 0.24 |
BUD31 | P41223 | 11 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
SNRPG | P62308 | 11 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
PRPF39 | Q86UA1 | 11 | T1DM | No | 0.17 | 0.00 | 0.06 | 0.19 |
PTPRK | Q15262 | 11 | T1DM | No | 0.18 | 0.00 | 0.00 | 0.18 |
GFM1 | Q96RP9 | 11 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
MRPL27 | Q9P0M9 | 11 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
CWF19L2 | Q2TBE0 | 11 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
MYBL1 | P10243 | 11 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
POTEF | A5A3E0 | 11 | – | No | 0.10 | 0.00 | 0.10 | 0.15 |
IFNG | P01579 | 10 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.35 | 0.34 |
PTPRC | P08575 | 10 | T1DM, T2DM, GDM | No | 0.18 | 0.00 | 0.09 | 0.22 |
ITGAV | P06756 | 10 | T1DM, GDM | No | 0.00 | 0.00 | 0.20 | 0.20 |
MRPL17 | Q9NRX2 | 10 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
NTN5 | Q8WTR8 | 10 | T1DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
CTNNB1 | P35222 | 10 | T1DM, T2DM, GDM | No | 0.06 | 0.00 | 0.14 | 0.16 |
PPEF2 | O14830 | 10 | – | No | 0.16 | 0.00 | 0.05 | 0.16 |
ANPEP | P15144 | 9 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.90 | 0.90 |
APP | P05067 | 9 | T1DM, T2DM, GDM, Other | No | 0.05 | 0.00 | 0.84 | 0.84 |
ROBO2 | Q9HCK4 | 9 | T2DM | No | 0.13 | 0.00 | 0.19 | 0.27 |
IL20RA | Q9UHF4 | 9 | T2DM | No | 0.00 | 0.00 | 0.25 | 0.25 |
MYOC | Q99972 | 9 | – | No | 0.06 | 0.00 | 0.23 | 0.24 |
CNTNAP1 | P78357 | 9 | T2DM | No | 0.00 | 0.00 | 0.19 | 0.19 |
SNRPA | P09012 | 9 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
EFL1 | Q7Z2Z2 | 9 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
EEF2 | P13639 | 9 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
PPP5C | P53041 | 9 | – | No | 0.16 | 0.00 | 0.05 | 0.16 |
NAA38 | Q9BRA0 | 9 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
POTEI | P0CG38 | 9 | – | No | 0.10 | 0.00 | 0.10 | 0.15 |
LSM6 | P62312 | 9 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
RHO | P08100 | 9 | T1DM, T2DM | No | 0.00 | 0.00 | 0.15 | 0.15 |
NGFR | P08138 | 8 | T1DM, T2DM | No | 0.50 | 0.90 | 0.90 | 0.99 |
MAG | P20916 | 8 | – | No | 0.24 | 0.90 | 0.73 | 0.98 |
LILRB3 | O75022 | 8 | – | No | 0.00 | 0.00 | 0.42 | 0.42 |
RTN1 | Q16799 | 8 | – | No | 0.17 | 0.00 | 0.31 | 0.41 |
ADAM22 | Q9P0K1 | 8 | T1DM | No | 0.00 | 0.00 | 0.36 | 0.36 |
PLRG1 | O43660 | 8 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
SF3B3 | Q15393 | 8 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
OLFM1 | Q99784 | 8 | – | No | 0.06 | 0.00 | 0.19 | 0.20 |
NTN1 | O95631 | 8 | T1DM, T2DM, GDM | No | 0.17 | 0.00 | 0.07 | 0.19 |
FGFR1 | P11362 | 8 | T1DM, T2DM | No | 0.18 | 0.00 | 0.00 | 0.17 |
LSM7 | Q9UK45 | 8 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
STK26 | Q9P289 | 8 | Other | No | 0.17 | 0.00 | 0.00 | 0.17 |
SRRM2 | Q9UQ35 | 8 | T2DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
PPP3CA | Q08209 | 8 | Other | No | 0.16 | 0.00 | 0.05 | 0.16 |
TTF1 | Q15361 | 8 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
PPP4C | P60510 | 8 | T1DM | No | 0.16 | 0.00 | 0.05 | 0.16 |
MYB | P10242 | 8 | T2DM, Other | No | 0.16 | 0.00 | 0.00 | 0.16 |
PPP2CB | P62714 | 8 | – | No | 0.16 | 0.00 | 0.05 | 0.16 |
SNRPD2 | P62316 | 8 | T2DM | No | 0.15 | 0.00 | 0.00 | 0.15 |
SNRPB | P14678 | 8 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
SNIP1 | Q8TAD8 | 8 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
ARHGDIA | P52565 | 7 | T1DM, Other | No | 0.00 | 0.90 | 0.00 | 0.90 |
RBM25 | P49756 | 7 | – | No | 0.35 | 0.00 | 0.00 | 0.35 |
SNRPF | P62306 | 7 | – | No | 0.22 | 0.00 | 0.00 | 0.22 |
SNW1 | Q13573 | 7 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
XAB2 | Q9HCS7 | 7 | GDM | No | 0.18 | 0.00 | 0.06 | 0.20 |
ROBO1 | Q9Y6N7 | 7 | – | No | 0.13 | 0.00 | 0.11 | 0.19 |
SF3B5 | Q9BWJ5 | 7 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
ASCC3 | Q8N3C0 | 7 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
MAP3K8 | P41279 | 7 | T2DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
CWC22 | Q9HCG8 | 7 | T1DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
CWC25 | Q9NXE8 | 7 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
MRPL20 | Q9BYC9 | 7 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
PPP1CA | P62136 | 7 | – | No | 0.16 | 0.00 | 0.05 | 0.16 |
LSM3 | P62310 | 7 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
PPEF1 | O14829 | 7 | – | No | 0.16 | 0.00 | 0.05 | 0.16 |
CNTN1 | Q12860 | 7 | T1DM | No | 0.08 | 0.00 | 0.12 | 0.15 |
LSM5 | Q9Y4Y9 | 7 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
EGFR | P00533 | 7 | T1DM, T2DM, GDM, Other | No | 0.07 | 0.00 | 0.12 | 0.15 |
SNRPD3 | P62318 | 7 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
MSRB1 | Q9NZV6 | 7 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
RTN4 | Q9NQC3 | 6 | T2DM | No | 0.24 | 0.90 | 0.90 | 0.99 |
KIAA0319L | Q8IZA0 | 6 | T1DM | No | 0.27 | 0.00 | 0.47 | 0.59 |
TNFSF13B | Q9Y275 | 6 | T1DM, T2DM, GDM | No | 0.00 | 0.00 | 0.44 | 0.44 |
PRPF19 | Q9UMS4 | 6 | – | No | 0.22 | 0.00 | 0.00 | 0.22 |
SF3A3 | Q12874 | 6 | T1DM | No | 0.20 | 0.00 | 0.00 | 0.20 |
HEATR6 | Q6AI08 | 6 | – | No | 0.18 | 0.00 | 0.06 | 0.20 |
NTNG1 | Q9Y2I2 | 6 | – | No | 0.20 | 0.00 | 0.00 | 0.20 |
TFIP11 | Q9UBB9 | 6 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
PTPRU | Q92729 | 6 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
NRXN2 | Q9P2S2 | 6 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
NTNG2 | Q96CW9 | 6 | T2DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
RPS2 | P15880 | 6 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
NTN3 | O00634 | 6 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
EFTUD2 | Q15029 | 6 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
MRPS9 | P82933 | 6 | T2DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
PRPF6 | O94906 | 6 | T1DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
RPL4 | P36578 | 6 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
DMTF1 | Q9Y222 | 6 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
SLU7 | O95391 | 6 | T1DM | No | 0.15 | 0.00 | 0.00 | 0.15 |
LINGO1 | Q96FE5 | 5 | T2DM | No | 0.48 | 0.90 | 0.90 | 0.99 |
OMG | P23515 | 5 | T2DM | No | 0.30 | 0.90 | 0.90 | 0.99 |
LGI1 | O95970 | 5 | Other | No | 0.00 | 0.00 | 0.29 | 0.29 |
RTN4RL1 | Q86UN2 | 5 | – | No | 0.00 | 0.00 | 0.29 | 0.29 |
MYCN | P04198 | 5 | T2DM | No | 0.00 | 0.00 | 0.26 | 0.26 |
PRPF40B | Q6NWY9 | 5 | – | No | 0.24 | 0.00 | 0.00 | 0.24 |
SF3B2 | Q13435 | 5 | – | No | 0.21 | 0.00 | 0.06 | 0.23 |
RBM22 | Q9NW64 | 5 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
CCDC130 | P13994 | 5 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
PTPRM | P28827 | 5 | T2DM | No | 0.18 | 0.00 | 0.00 | 0.18 |
HFM1 | A2PYH4 | 5 | T1DM, T2DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
PPT1 | P50897 | 5 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
RPL3 | P39023 | 5 | – | No | 0.17 | 0.00 | 0.00 | 0.16 |
MYBL2 | P10244 | 5 | T2DM | No | 0.16 | 0.00 | 0.00 | 0.16 |
MRPL3 | P09001 | 5 | T2DM | No | 0.17 | 0.00 | 0.00 | 0.16 |
CDC5L | Q99459 | 5 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
RPS16 | P62249 | 5 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
SNRPE | P62304 | 5 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
POTEE | Q6S8J3 | 5 | – | No | 0.10 | 0.00 | 0.10 | 0.15 |
LSM10 | Q969L4 | 5 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
PRPF8 | Q6P2Q9 | 4 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
CDC40 | O60508 | 4 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
PTPRF | P10586 | 4 | T2DM | No | 0.18 | 0.00 | 0.00 | 0.18 |
SF3A1 | Q15459 | 4 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
LSM4 | Q9Y4Z0 | 4 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
AQR | O60306 | 4 | T2DM | No | 0.17 | 0.00 | 0.00 | 0.17 |
SNRPC | P09234 | 4 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
RBMX2 | Q9Y388 | 4 | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
TNFRSF19 | Q9NS68 | 3 | – | No | 0.00 | 0.00 | 0.88 | 0.88 |
RHOH | Q15669 | 3 | – | No | 0.10 | 0.00 | 0.61 | 0.64 |
RTN4RL2 | Q86UN3 | 3 | – | No | 0.00 | 0.00 | 0.27 | 0.27 |
ROBO3 | Q96MS0 | 3 | – | No | 0.13 | 0.00 | 0.14 | 0.22 |
CRNKL1 | Q9BZJ0 | 3 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
SYF2 | O95926 | 3 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
BCAS2 | O75934 | 3 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
SF3A2 | Q15428 | 3 | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
SNRNP200 | O75643 | 3 | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
PPP1R42 | Q7Z4L9 | 3 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
SNRNP40 | Q96DI7 | 3 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
DAW1 | Q8N136 | 3 | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
SF3B1 | O75533 | 2 | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
WDR25 | Q64LD2 | - | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
GPATCH8 | Q9UKJ3 | - | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
ISY1 | Q9ULR0 | - | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
YJU2 | Q9BW85 | - | – | No | 0.18 | 0.00 | 0.00 | 0.18 |
ZMAT2 | Q96NC0 | - | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
PRPF4 | O43172 | - | – | No | 0.16 | 0.00 | 0.00 | 0.16 |
PPP5D1 | E7EU14 | - | – | No | 0.16 | 0.00 | 0.05 | 0.16 |
POTEJ | P0CG39 | - | – | No | 0.10 | 0.00 | 0.10 | 0.15 |
TNF | P01375 | - | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.88 | 0.88 |
MOG | Q16653 | - | T1DM, Other | No | 0.00 | 0.00 | 0.34 | 0.34 |
PPP1R11 | O60927 | - | T1DM | No | 0.18 | 0.00 | 0.08 | 0.22 |
CWC15 | Q9P013 | - | – | No | 0.21 | 0.00 | 0.00 | 0.21 |
SF3B4 | Q15427 | - | T2DM | No | 0.18 | 0.00 | 0.00 | 0.18 |
NRXN1 | Q9ULB1 | - | T1DM | No | 0.18 | 0.00 | 0.00 | 0.18 |
SRRM3 | A6NNA2 | - | – | No | 0.17 | 0.00 | 0.00 | 0.17 |
PPT2 | Q9UMR5 | - | T2DM | No | 0.16 | 0.00 | 0.00 | 0.16 |
PRPF3 | O43395 | - | T1DM | No | 0.16 | 0.00 | 0.00 | 0.16 |
LSM2 | Q9Y333 | - | – | No | 0.15 | 0.00 | 0.00 | 0.15 |
Interaction partner | UniProt ID | Diabetes textmining % | Diabetes associations | Suggested diabetes biomarker | Experimental score | Database score | Textmining score | Combined score |
---|---|---|---|---|---|---|---|---|
CRP | ||||||||
OLR1 | P78380 | 26 | T2DM, GDM | RHAPSODY partner suggestion | 0.00 | 0.00 | 0.88 | 0.88 |
C1QA | P02745 | 13 | – | No | 0.57 | 0.60 | 0.26 | 0.86 |
FCN2 | Q15485 | 11 | T1DM | Network expansion | 0.27 | 0.00 | 0.83 | 0.87 |
C4A | P0C0L4 | 11 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.72 | 0.72 |
CFH | P08603 | 10 | T1DM, T2DM, GDM | Network expansion | 0.73 | 0.00 | 0.90 | 0.97 |
FCGR2A | P12318 | 10 | T1DM, T2DM, Other | No | 0.46 | 0.00 | 0.90 | 0.94 |
C3 | P01024 | 10 | T1DM, T2DM, GDM, Other | Abbasi et al, 2016 | 0.48 | 0.00 | 0.66 | 0.82 |
FCGR2B | P31994 | 10 | T2DM, Other | No | 0.00 | 0.00 | 0.75 | 0.75 |
C4BPA | P04003 | 9 | – | No | 0.42 | 0.00 | 0.54 | 0.72 |
FCN1 | O00602 | 8 | T1DM | No | 0.30 | 0.00 | 0.86 | 0.90 |
CFHR4 | Q92496 | 6 | – | No | 0.57 | 0.00 | 0.76 | 0.89 |
FCGR1A | P12314 | - | – | No | 0.00 | 0.00 | 0.94 | 0.94 |
FAS | ||||||||
TNFRSF10A | O00220 | 22 | T1DM, T2DM, GDM | No | 0.00 | 0.60 | 0.42 | 0.76 |
MAP3K5 | Q99683 | 17 | T1DM, T2DM | No | 0.64 | 0.90 | 0.00 | 0.96 |
CAV1 | Q03135 | 16 | T1DM, T2DM, GDM, Other | No | 0.48 | 0.00 | 0.46 | 0.71 |
FASLG | P48023 | 12 | T1DM, T2DM, Other | No | 0.65 | 0.90 | 0.90 | 1.00 |
FAF1 | Q9UNN5 | 12 | T2DM | No | 0.50 | 0.90 | 0.45 | 0.97 |
TNFRSF10B | O14763 | 11 | T1DM, T2DM | No | 0.29 | 0.60 | 0.00 | 0.70 |
PLCG1 | P19174 | 11 | T2DM | No | 0.27 | 0.00 | 0.61 | 0.70 |
RIPK1 | Q13546 | 10 | – | No | 0.44 | 0.90 | 0.47 | 0.97 |
CASP10 | Q92851 | 10 | – | No | 0.52 | 0.90 | 0.47 | 0.97 |
FAIM2 | Q9BWQ8 | 10 | T2DM, GDM | No | 0.27 | 0.90 | 0.00 | 0.92 |
CFLAR | O15519 | 9 | T2DM | No | 0.49 | 0.90 | 0.45 | 0.97 |
SRC | P12931 | 9 | T1DM, T2DM | No | 0.48 | 0.90 | 0.20 | 0.95 |
BTK | Q06187 | 9 | – | No | 0.00 | 0.90 | 0.07 | 0.90 |
SYK | P43405 | 9 | Other | No | 0.00 | 0.90 | 0.00 | 0.90 |
SUMO1 | P63165 | 9 | T1DM, T2DM | No | 0.48 | 0.00 | 0.61 | 0.79 |
CASP8 | Q14790 | 8 | T1DM, T2DM | No | 0.53 | 0.90 | 0.94 | 1.00 |
FADD | Q13158 | 8 | T1DM | No | 0.95 | 0.90 | 0.91 | 1.00 |
EGFR | P00533 | 7 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.75 | 0.75 |
DAXX | Q9UER7 | - | T1DM | No | 0.66 | 0.90 | 0.39 | 0.98 |
TRADD | Q15628 | - | – | No | 0.46 | 0.90 | 0.28 | 0.96 |
CALM1 | P0DP23 | - | T1DM, GDM | No | 0.80 | 0.00 | 0.00 | 0.80 |
GDF15 | ||||||||
RET | P07949 | 5 | T1DM, T2DM, Other | No | 0.80 | 0.00 | 0.27 | 0.85 |
GFRAL | Q6UXV0 | 4 | T2DM | No | 0.80 | 0.00 | 0.90 | 0.98 |
IL18R1 | ||||||||
IL18 | Q14116 | 19 | T1DM, T2DM, GDM, Other | Abbasi et al, 2016 | 0.93 | 0.90 | 0.91 | 1.00 |
IL37 | Q9NZH6 | 13 | T1DM, T2DM, GDM | No | 0.28 | 0.60 | 0.78 | 0.93 |
IL18RAP | O95256 | 12 | T1DM | No | 0.80 | 0.90 | 0.91 | 1.00 |
SIGIRR | Q6IA17 | 12 | – | No | 0.00 | 0.60 | 0.60 | 0.84 |
RTN4R | ||||||||
ANPEP | P15144 | 9 | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.90 | 0.90 |
APP | P05067 | 9 | T1DM, T2DM, GDM, Other | No | 0.05 | 0.00 | 0.84 | 0.84 |
NGFR | P08138 | 8 | T1DM, T2DM | No | 0.50 | 0.90 | 0.90 | 0.99 |
MAG | P20916 | 8 | – | No | 0.24 | 0.90 | 0.73 | 0.98 |
ARHGDIA | P52565 | 7 | T1DM, Other | No | 0.00 | 0.90 | 0.00 | 0.90 |
RTN4 | Q9NQC3 | 6 | T2DM | No | 0.24 | 0.90 | 0.90 | 0.99 |
LINGO1 | Q96FE5 | 5 | T2DM | No | 0.48 | 0.90 | 0.90 | 0.99 |
OMG | P23515 | 5 | T2DM | No | 0.30 | 0.90 | 0.90 | 0.99 |
TNFRSF19 | Q9NS68 | 3 | – | No | 0.00 | 0.00 | 0.88 | 0.88 |
TNF | P01375 | - | T1DM, T2DM, GDM, Other | No | 0.00 | 0.00 | 0.88 | 0.88 |
Summary table showing all interaction partners for each target together with additional information:
UniProt ID (UniProt): Link to UniProt for additional information on the target
Diabetes textmining % (in-house data): Percentage of co-mentions from textmining relating to diabetes vs. all other diseases. For more information on the data source, see Westergaard et al. PLoS Computational Biology 2018)
Diabetes associations (Open Targets):
Gene-disease (diabetes mellitus) association through experiments or
clinical trials. Direct associations with T1DM, T2DM and GDM are shown
specifically, while all other diabetes mellitus diseases are included in
“Other”.
Suggested biomarker: Known and suggested
biomarkers from Abbasi
et al, 2016, RHAPSODY partners (collected by the RHAPSODY biomarker
taskforce) and based on PPI-network analysis of known biomarkers
(in-house Analysis).
Experimental score: STRING experimental score
derived from experimental data, such as, affinity chromatography. The
experimental data is extracted from the databases BIND, DIP, GRID, HPRD,
IntAct, MINT, and PID.
Database score: STRING database score derived
from curated data of Biocarta, BioCyc, GO, KEGG, and Reactome.
Textmining score: STRING textmining score derived from co-occurrence of gene/protein names in abstracts
Combined score: STRING combined score of interaction confidence. Interactions with a combined score > 0.7 is deemed a high-confidence interaction.
High-confidence interaction partners with a confidence score ≥ 0.156 are shown in blue, while suggested interaction partners are shown in gray.
en-dash (-) indicates that no information was available for the target.
Over-represented terms were found for:
Biological process GO-terms, Cellular component GO-terms, Molecular function GO-terms, KEGG pathways, Reactome pathways, Wikipathways, GLAD4U diseases, GLAD4U drugs
Term | Source link | Targets | Enrichment ratio | FDR |
---|---|---|---|---|
Biological process GO-terms | ||||
membrane lipid metabolic process | link | ENPP7 | 63 | 0.00e+00 |
peptide catabolic process | link | GGT1 | 56 | 5.37e-05 |
cellular modified amino acid catabolic process | link | GGT1 | 53 | 5.85e-05 |
interferon-gamma production | link | IL18R1 | 53 | 5.08e-04 |
protein activation cascade | link | CRP | 47 | 0.00e+00 |
cellular modified amino acid biosynthetic process | link | GGT1 | 39 | 1.38e-05 |
natural killer cell activation | link | IL18R1 | 38 | 0.060 |
cofactor catabolic process | link | GGT1 | 36 | 1.51e-06 |
liposaccharide metabolic process | link | ENPP7 | 36 | 5.55e-05 |
cellular modified amino acid metabolic process | link | GGT1 | 34 | 0.00e+00 |
NIK/NF-kappaB signaling | link | IL18R1 | 34 | 0.007 |
production of molecular mediator of immune response | link | IL18R1 | 29 | 0.001 |
ammonium ion metabolic process | link | ENPP7 | 27 | 1.22e-06 |
fatty acid derivative metabolic process | link | GGT1 | 25 | 7.09e-10 |
necrotic cell death | link | FAS | 25 | 8.41e-10 |
acute inflammatory response | link | CRP | 24 | 0.00e+00 |
sulfur compound metabolic process | link | GGT1 | 24 | 0.00e+00 |
humoral immune response | link | CRP | 23 | 0.00e+00 |
interleukin-8 production | link | CRP | 23 | 1.77e-06 |
response to xenobiotic stimulus | link | GGT1 | 20 | 6.29e-14 |
adaptive thermogenesis | link | IL18R1 | 19 | 0.196 |
lymphocyte mediated immunity | link | IL18R1 | 18 | 0.028 |
regulation of DNA-binding transcription factor activity | link | IL18R1 | 17 | 0.001 |
lymphocyte activation involved in immune response | link | IL18R1 | 17 | 0.215 |
positive regulation of cytokine production | link | IL18R1 | 16 | 0.001 |
phagocytosis | link | CRP | 15 | 1.18e-12 |
extrinsic apoptotic signaling pathway | link | FAS | 15 | 0.00e+00 |
adaptive immune response | link | IL18R1 | 15 | 0.007 |
lymphocyte mediated immunity | link | CRP | 14 | 1.33e-10 |
regulation of immune effector process | link | IL18R1 | 14 | 0.008 |
foam cell differentiation | link | CRP | 12 | 0.218 |
activation of protein kinase activity | link | GDF15 | 12 | 4.72e-14 |
response to transforming growth factor beta | link | GDF15 | 11 | 2.11e-08 |
adaptive immune response | link | CRP | 10 | 2.16e-10 |
fatty acid metabolic process | link | GGT1 | 10 | 2.49e-06 |
dicarboxylic acid metabolic process | link | GGT1 | 10 | 0.153 |
regulation of apoptotic signaling pathway | link | FAS | 10 | 0.00e+00 |
positive regulation of proteolysis | link | FAS | 10 | 0.00e+00 |
lipid catabolic process | link | ENPP7 | 10 | 0.061 |
response to BMP | link | GDF15 | 10 | 3.21e-04 |
cytokine secretion | link | CRP | 9 | 1.60e-04 |
organic acid biosynthetic process | link | GGT1 | 9 | 7.82e-06 |
response to estradiol | link | GGT1 | 9 | 0.187 |
organic acid biosynthetic process | link | GPT | 9 | 5.54e-08 |
regulation of peptidase activity | link | FAS | 9 | 0.00e+00 |
transmembrane receptor protein serine/threonine kinase signaling pathway | link | GDF15 | 9 | 5.61e-08 |
cofactor biosynthetic process | link | GGT1 | 8 | 0.007 |
small molecule catabolic process | link | GPT | 8 | 1.27e-07 |
phospholipid metabolic process | link | ENPP7 | 8 | 0.040 |
regulation of protein serine/threonine kinase activity | link | GDF15 | 8 | 8.41e-11 |
protein kinase B signaling | link | GDF15 | 8 | 1.44e-05 |
feeding behavior | link | GDF15 | 8 | 0.048 |
response to mechanical stimulus | link | FAS | 7 | 3.11e-06 |
response to peptide | link | GDF15 | 7 | 2.76e-09 |
response to axon injury | link | RTN4R | 7 | 0.009 |
response to molecule of bacterial origin | link | GGT1 | 6 | 0.112 |
cellular response to external stimulus | link | FAS | 6 | 1.10e-07 |
stress-activated protein kinase signaling cascade | link | FAS | 6 | 1.40e-06 |
T cell activation | link | IL18R1 | 6 | 0.630 |
multicellular organismal homeostasis | link | IL18R1 | 6 | 0.640 |
leukocyte differentiation | link | IL18R1 | 6 | 0.678 |
regulation of developmental growth | link | GDF15 | 6 | 8.03e-04 |
maintenance of location | link | CRP | 5 | 0.018 |
regulation of inflammatory response | link | GGT1 | 5 | 0.148 |
cellular amino acid metabolic process | link | GPT | 5 | 0.003 |
cellular response to environmental stimulus | link | FAS | 5 | 2.62e-05 |
negative regulation of growth | link | GDF15 | 5 | 0.004 |
negative regulation of cell projection organization | link | RTN4R | 5 | 0.001 |
regeneration | link | RTN4R | 5 | 0.001 |
regulation of peptide secretion | link | CRP | 4 | 0.028 |
lipid localization | link | CRP | 4 | 0.032 |
defense response to other organism | link | CRP | 4 | 0.057 |
reactive oxygen species metabolic process | link | CRP | 4 | 0.354 |
cellular amino acid metabolic process | link | GGT1 | 4 | 0.431 |
response to nutrient levels | link | FAS | 4 | 1.40e-04 |
response to oxygen levels | link | FAS | 4 | 0.001 |
multicellular organism growth | link | GDF15 | 4 | 0.150 |
cell-cell fusion | link | GDF15 | 4 | 0.510 |
syncytium formation | link | GDF15 | 4 | 0.516 |
axon development | link | RTN4R | 4 | 1.74e-08 |
negative regulation of nervous system development | link | RTN4R | 4 | 3.16e-04 |
negative regulation of cell development | link | RTN4R | 4 | 0.002 |
response to nutrient levels | link | GDF15 | 3 | 0.063 |
regulation of neuron projection development | link | RTN4R | 3 | 9.25e-05 |
regulation of cell morphogenesis | link | RTN4R | 3 | 0.006 |
developmental growth involved in morphogenesis | link | RTN4R | 3 | 0.023 |
negative regulation of growth | link | RTN4R | 3 | 0.045 |
forebrain development | link | RTN4R | 3 | 0.095 |
muscle cell differentiation | link | GDF15 | 2 | 0.269 |
cell growth | link | RTN4R | 2 | 0.039 |
regulation of developmental growth | link | RTN4R | 2 | 0.295 |
negative regulation of response to external stimulus | link | RTN4R | 2 | 0.474 |
regulation of response to wounding | link | RTN4R | 2 | 0.522 |
regulation of anatomical structure size | link | RTN4R | 1 | 0.956 |
Cellular component GO-terms | ||||
membrane region | link | FAS | 8 | 1.15e-12 |
dendritic shaft | link | RTN4R | 4 | 0.669 |
membrane region | link | RTN4R | 3 | 0.002 |
glutamatergic synapse | link | RTN4R | 3 | 0.005 |
anchored component of membrane | link | RTN4R | 3 | 0.254 |
presynapse | link | RTN4R | 2 | 0.060 |
neuronal cell body | link | RTN4R | 2 | 0.062 |
GLAD4U diseases | ||||
Parotitis | link | IL18R1 | 70 | 0.298 |
Purpura, Thrombocytopenic | link | IL18R1 | 53 | 0.033 |
SRS-A | link | GGT1 | 51 | 0.002 |
Purpura, Thrombocytopenic, Idiopathic | link | IL18R1 | 49 | 0.037 |
Hepatitis, Alcoholic | link | GGT1 | 45 | 2.44e-04 |
Purpura | link | IL18R1 | 43 | 0.043 |
Bacteremia | link | CRP | 40 | 3.38e-09 |
Microvascular Angina | link | CRP | 40 | 9.59e-04 |
Liver Cirrhosis, Alcoholic | link | GGT1 | 39 | 3.64e-04 |
Selective immunoglobulin G deficiency | link | CRP | 38 | 4.76e-07 |
febrile neutropenia | link | CRP | 38 | 8.80e-05 |
Actinomycetales Infections | link | IL18R1 | 38 | 6.83e-04 |
Mycobacterial infection | link | IL18R1 | 37 | 6.83e-04 |
Mycobacterium Infections | link | IL18R1 | 37 | 6.83e-04 |
Acute necrotizing pancreatitis | link | CRP | 36 | 0.014 |
Environmental allergy | link | IL18R1 | 36 | 0.005 |
Blood Loss, Surgical | link | CRP | 34 | 8.97e-09 |
Periventricular leucomalacia | link | FAS | 34 | 0.005 |
Streptococcal Infections | link | CRP | 33 | 1.07e-08 |
Vitamin A Deficiency | link | CRP | 33 | 0.016 |
Liver Diseases, Alcoholic | link | GGT1 | 31 | 4.71e-06 |
Psoriasis | link | IL18R1 | 31 | 0.001 |
Arteritis | link | CRP | 30 | 1.97e-05 |
Hypoalbuminaemia | link | CRP | 30 | 0.018 |
Postoperative Hemorrhage | link | CRP | 30 | 0.018 |
Graves Disease | link | IL18R1 | 30 | 0.008 |
Osteoarthritis, Knee | link | IL18R1 | 30 | 0.069 |
Ischemic Attack, Transient | link | CRP | 28 | 2.89e-05 |
Kidney Tubular Necrosis, Acute | link | CRP | 28 | 0.002 |
Retinal Drusen | link | CRP | 28 | 0.002 |
Alcoholic fatty liver | link | GGT1 | 28 | 4.57e-05 |
Angina Pectoris | link | CRP | 27 | 6.42e-09 |
Community-Acquired Infections | link | CRP | 27 | 2.74e-04 |
Escherichia coli Infections | link | CRP | 26 | 4.46e-07 |
Mumps | link | IL18R1 | 26 | 0.492 |
Intracranial Arteriosclerosis | link | CRP | 25 | 0.003 |
major adverse cardiac events (mace) | link | CRP | 25 | 0.003 |
Osteoarthritis | link | IL18R1 | 25 | 0.013 |
Malabsorption Syndromes | link | IL18R1 | 24 | 0.099 |
Smallpox | link | IL18R1 | 24 | 0.099 |
renal transplant failure | link | CRP | 23 | 1.41e-07 |
Staphylococcal Infections | link | CRP | 23 | 5.11e-04 |
Enterocolitis | link | CRP | 23 | 0.004 |
Microvascular Angina | link | GGT1 | 23 | 0.630 |
Gastroenteritis | link | IL18R1 | 23 | 6.37e-04 |
Asthma | link | IL18R1 | 23 | 6.37e-04 |
Crohn Disease | link | IL18R1 | 23 | 0.002 |
Occupational Diseases | link | IL18R1 | 23 | 0.100 |
Acute coronary syndrome | link | CRP | 22 | 1.99e-07 |
Pregnancy Third Trimester | link | CRP | 22 | 1.15e-05 |
Acute-Phase Reaction | link | CRP | 22 | 7.94e-05 |
Arteriovenous Fistula | link | CRP | 22 | 0.031 |
Respiratory Hypersensitivity | link | IL18R1 | 22 | 0.002 |
Gram-Positive Bacterial Infections | link | IL18R1 | 22 | 0.017 |
Urinary Tract Infections | link | CRP | 21 | 0.005 |
Leprosy | link | IL18R1 | 21 | 0.572 |
Coronary Stenosis | link | CRP | 20 | 2.08e-06 |
Cross Infection | link | CRP | 20 | 2.45e-06 |
disease activity score 28 joint in rheumatoid arthritis | link | CRP | 20 | 0.005 |
Pulmonary Embolism | link | CRP | 20 | 0.006 |
Hyperoxia | link | FAS | 20 | 4.52e-04 |
Lupus Erythematosus, Systemic | link | CRP | 19 | 0.00e+00 |
Lupus erythematosus | link | CRP | 19 | 0.00e+00 |
Chronic pericementitis | link | CRP | 19 | 1.95e-05 |
Arthritis, Reactive | link | CRP | 19 | 2.50e-05 |
Peripheral Vascular Diseases | link | CRP | 19 | 2.50e-05 |
Pneumonia, Bacterial | link | CRP | 19 | 9.47e-04 |
Carotid Stenosis | link | CRP | 19 | 0.001 |
Congenital choledochal cyst | link | GGT1 | 19 | 0.690 |
hepatic necrosis | link | FAS | 19 | 8.87e-06 |
Rubella | link | IL18R1 | 19 | 0.601 |
Organ Transplantation | link | CRP | 18 | 3.38e-09 |
Systemic Inflammatory Response Syndrome | link | CRP | 18 | 1.41e-07 |
Angina, Unstable | link | CRP | 18 | 1.82e-04 |
Mucocutaneous Lymph Node Syndrome | link | CRP | 18 | 0.001 |
Embolism | link | CRP | 18 | 0.007 |
creatinine clearance | link | CRP | 18 | 0.007 |
Paroxysmal tachycardia NOS | link | CRP | 18 | 0.284 |
Tachycardia, Paroxysmal | link | CRP | 18 | 0.284 |
pain crisis | link | CRP | 18 | 0.284 |
cessation | link | GGT1 | 18 | 0.151 |
Inflammatory Bowel Diseases | link | IL18R1 | 18 | 0.004 |
Carotid Artery Diseases | link | CRP | 17 | 1.70e-07 |
Periodontitis | link | CRP | 17 | 4.64e-05 |
Pneumococcal Infections | link | CRP | 17 | 2.28e-04 |
Shock, Septic | link | CRP | 17 | 2.28e-04 |
adverse cardiovascular events | link | CRP | 17 | 0.002 |
Sleep Apnea Syndromes | link | CRP | 17 | 0.008 |
Respiratory Sounds | link | CRP | 17 | 0.008 |
Sleep Apnea, Obstructive | link | CRP | 17 | 0.008 |
Hematoma | link | CRP | 17 | 0.304 |
Bronchial Diseases | link | IL18R1 | 17 | 0.005 |
Hypersensitivity | link | IL18R1 | 17 | 0.005 |
Preterm Infant | link | IL18R1 | 17 | 0.033 |
Respiratory Syncytial Virus Infections | link | IL18R1 | 17 | 0.033 |
Celiac Disease | link | IL18R1 | 17 | 0.161 |
glomerular disease | link | CRP | 16 | 9.27e-09 |
Proteinuria | link | CRP | 16 | 5.25e-08 |
Periodontal Diseases | link | CRP | 16 | 4.98e-05 |
Hip Injuries | link | CRP | 16 | 0.053 |
Lymphopenia | link | FAS | 16 | 8.00e-07 |
Lymphocytosis | link | FAS | 16 | 0.006 |
Bronchitis | link | IL18R1 | 16 | 0.038 |
Sepsis | link | CRP | 15 | 4.20e-07 |
Kidney Transplantation | link | CRP | 15 | 4.27e-07 |
Septicemia | link | CRP | 15 | 4.46e-07 |
Vasculitis | link | CRP | 15 | 4.46e-07 |
Diabetic Angiopathies | link | CRP | 15 | 7.18e-05 |
Reperfusion Injury | link | CRP | 15 | 7.54e-05 |
Lung Diseases, Fungal | link | CRP | 15 | 7.94e-05 |
Coronary Thrombosis | link | CRP | 15 | 0.002 |
Fibromyalgia | link | CRP | 15 | 0.056 |
Tachycardia, Sinus | link | CRP | 15 | 0.320 |
Bacterial Infections | link | CRP | 14 | 5.22e-11 |
visceral obesity | link | CRP | 14 | 1.82e-05 |
Urination Disorders | link | CRP | 14 | 1.06e-04 |
Periodontal Pocket | link | CRP | 14 | 1.26e-04 |
Hypertriglyceridemia | link | CRP | 14 | 5.29e-04 |
Myocardial Reperfusion Injury | link | CRP | 14 | 0.013 |
Poland anomaly | link | CRP | 14 | 0.014 |
Intraoperative Complications | link | CRP | 14 | 0.334 |
visceral obesity | link | GGT1 | 14 | 0.011 |
Hepatitis, Alcoholic | link | GPT | 14 | 0.622 |
Inflammation | link | IL18R1 | 14 | 6.83e-04 |
Respiratory Tract Infections | link | IL18R1 | 14 | 0.047 |
Traumatic optic neuropathy | link | RTN4R | 14 | 0.181 |
Gram-Positive Bacterial Infections | link | CRP | 13 | 2.50e-07 |
Kidney Failure | link | CRP | 13 | 3.33e-07 |
Hyperlipidemias | link | CRP | 13 | 1.58e-04 |
Urological Manifestations | link | CRP | 13 | 1.67e-04 |
Pneumonia | link | CRP | 13 | 1.74e-04 |
Pneumonia, Pneumococcal | link | CRP | 13 | 1.74e-04 |
pneumonitis | link | CRP | 13 | 1.82e-04 |
Aortic Diseases | link | CRP | 13 | 8.81e-04 |
Chest Pain | link | CRP | 13 | 0.004 |
Coronary Restenosis | link | CRP | 13 | 0.015 |
Critical Illness | link | CRP | 13 | 0.015 |
venous thromboembolism | link | CRP | 13 | 0.016 |
Anovulation | link | CRP | 13 | 0.350 |
Fatty Liver | link | GGT1 | 13 | 1.42e-04 |
hepatic steatosis | link | GGT1 | 13 | 1.64e-04 |
Multiple Sclerosis, Relapsing-Remitting | link | FAS | 13 | 6.07e-04 |
Toxemia | link | FAS | 13 | 0.035 |
Systemic sclerosis, diffuse | link | GDF15 | 13 | 0.056 |
Drug interaction with food | link | GDF15 | 13 | 0.221 |
Hemorrhage | link | CRP | 12 | 1.21e-05 |
Kidney Failure, Chronic | link | CRP | 12 | 4.02e-05 |
Spondylarthropathies | link | CRP | 12 | 9.59e-04 |
Spondylarthritis | link | CRP | 12 | 0.001 |
Macular Degeneration | link | CRP | 12 | 0.001 |
Urticaria | link | CRP | 12 | 0.088 |
Graft Occlusion, Vascular | link | CRP | 12 | 0.364 |
Hyperuricemia | link | GPT | 12 | 0.657 |
Erythema | link | FAS | 12 | 0.013 |
Vaccinia | link | IL18R1 | 12 | 0.782 |
Hypertension, Pulmonary | link | GDF15 | 12 | 3.49e-04 |
Hypertrophy, Left Ventricular | link | GDF15 | 12 | 0.018 |
Bronchopulmonary dysplasia of newborn | link | GDF15 | 12 | 0.069 |
Connective Tissue Diseases | link | CRP | 11 | 1.13e-12 |
Brain Ischemia | link | CRP | 11 | 9.39e-05 |
Albuminuria | link | CRP | 11 | 0.006 |
Cerebral Infarction | link | CRP | 11 | 0.021 |
Diabetic Neuropathies | link | CRP | 11 | 0.091 |
Peritonitis | link | CRP | 11 | 0.100 |
Peripheral Vascular Diseases | link | GGT1 | 11 | 0.327 |
Death | link | FAS | 11 | 0.00e+00 |
Thyroiditis | link | FAS | 11 | 0.005 |
Bronchiolitis | link | IL18R1 | 11 | 0.290 |
Cachexia | link | GDF15 | 11 | 0.270 |
Autoimmune Diseases | link | CRP | 10 | 0.00e+00 |
Coronary Artery Disease | link | CRP | 10 | 2.80e-08 |
Cerebrovascular Disorders | link | CRP | 10 | 1.77e-06 |
Ischemia | link | CRP | 10 | 1.91e-06 |
Rupture | link | CRP | 10 | 1.46e-04 |
Dyslipidaemia | link | CRP | 10 | 5.29e-04 |
treatment failure | link | CRP | 10 | 0.002 |
Fever | link | CRP | 10 | 0.002 |
Spondylitis | link | CRP | 10 | 0.003 |
Diabetes, Gestational | link | CRP | 10 | 0.007 |
Postoperative Complications | link | CRP | 10 | 0.008 |
Thromboembolism | link | CRP | 10 | 0.026 |
time in therapeutic range | link | CRP | 10 | 0.109 |
Prinzmetal angina | link | CRP | 10 | 0.112 |
Hyperinsulinism | link | GGT1 | 10 | 0.009 |
Liver Cirrhosis | link | GGT1 | 10 | 0.033 |
Carotid Artery Diseases | link | GGT1 | 10 | 0.110 |
Hyperuricemia | link | GGT1 | 10 | 0.944 |
Drug interaction with drug | link | FAS | 10 | 0.00e+00 |
Hodgkin Disease | link | FAS | 10 | 6.46e-07 |
Lung Diseases | link | IL18R1 | 10 | 0.094 |
Respiratory Tract Diseases | link | IL18R1 | 10 | 0.100 |
Bacterial Infections | link | IL18R1 | 10 | 0.321 |
Growth Disorders | link | GDF15 | 10 | 3.48e-06 |
Bone Neoplasms | link | GDF15 | 10 | 7.77e-05 |
Arteriosclerosis | link | CRP | 9 | 1.03e-07 |
Arterial Occlusive Diseases | link | CRP | 9 | 1.03e-07 |
Kidney Diseases | link | CRP | 9 | 2.04e-07 |
Rheumatic Diseases | link | CRP | 9 | 4.15e-07 |
Coronary Disease | link | CRP | 9 | 5.17e-07 |
Respiratory Tract Infections | link | CRP | 9 | 1.21e-06 |
Myocardial Infarction | link | CRP | 9 | 2.65e-05 |
Thrombosis | link | CRP | 9 | 8.20e-04 |
Gestational hypertension | link | CRP | 9 | 9.11e-04 |
Preterm rupture of membranes | link | CRP | 9 | 0.001 |
Brain Infarction | link | CRP | 9 | 0.033 |
Aortic Aneurysm | link | CRP | 9 | 0.037 |
Fistula | link | CRP | 9 | 0.120 |
Hip Fractures | link | CRP | 9 | 0.134 |
Apnea | link | CRP | 9 | 0.138 |
Current Non-smoker | link | CRP | 9 | 0.138 |
Abscess | link | CRP | 9 | 0.436 |
Metabolic Syndrome | link | GGT1 | 9 | 0.011 |
Lymphoma, B-Cell | link | FAS | 9 | 1.80e-08 |
Brain Death | link | FAS | 9 | 2.03e-06 |
Tumor Virus Infections | link | FAS | 9 | 4.36e-06 |
Lymphoma, T-Cell, Peripheral | link | FAS | 9 | 0.021 |
Xerostomia | link | FAS | 9 | 0.023 |
dry mouth | link | FAS | 9 | 0.023 |
Pathologic Processes | link | IL18R1 | 9 | 0.035 |
Anorexia | link | GDF15 | 9 | 0.139 |
beta-Thalassemia | link | GDF15 | 9 | 0.788 |
Vascular Diseases | link | CRP | 8 | 9.27e-09 |
Myocardial Ischemia | link | CRP | 8 | 9.45e-07 |
Infarction | link | CRP | 8 | 3.11e-05 |
Chorioamnionitis | link | CRP | 8 | 0.002 |
Wounds and Injuries | link | CRP | 8 | 0.005 |
Hypercholesterolemia | link | CRP | 8 | 0.014 |
Glucose Intolerance | link | CRP | 8 | 0.045 |
adverse events | link | CRP | 8 | 0.049 |
Fatigue | link | CRP | 8 | 0.142 |
Peritoneal Diseases | link | CRP | 8 | 0.142 |
Kidney Failure, Acute | link | CRP | 8 | 0.161 |
Ventricular Dysfunction, Left | link | CRP | 8 | 0.161 |
Arrhythmia, Sinus | link | CRP | 8 | 0.454 |
Wound Infection | link | CRP | 8 | 0.454 |
Fatigue Syndrome, Chronic | link | CRP | 8 | 0.482 |
Liver Diseases, Alcoholic | link | GPT | 8 | 0.507 |
drug-induced liver injury | link | GPT | 8 | 0.884 |
Necrosis | link | FAS | 8 | 1.00e-12 |
Lymphoma, Low-Grade | link | FAS | 8 | 9.41e-08 |
Leukopenia | link | FAS | 8 | 0.005 |
Cross Infection | link | FAS | 8 | 0.013 |
Goiter | link | FAS | 8 | 0.013 |
Splenomegaly | link | FAS | 8 | 0.088 |
Sezary Syndrome | link | FAS | 8 | 0.096 |
Thyroiditis, Autoimmune | link | FAS | 8 | 0.096 |
overall survival | link | GDF15 | 8 | 6.73e-10 |
major adverse cardiac events (mace) | link | GDF15 | 8 | 0.837 |
Spinal Cord Injuries | link | RTN4R | 8 | 0.325 |
Chronic Disease | link | CRP | 7 | 2.43e-06 |
Arthritis | link | CRP | 7 | 5.77e-06 |
Urologic Diseases | link | CRP | 7 | 1.27e-05 |
Joint Diseases | link | CRP | 7 | 7.18e-05 |
Pregnancy Complications | link | CRP | 7 | 9.39e-05 |
Hyperinsulinism | link | CRP | 7 | 0.003 |
Metabolic Syndrome | link | CRP | 7 | 0.004 |
glomerular filtration rate | link | CRP | 7 | 0.021 |
Aneurysm | link | CRP | 7 | 0.061 |
Body Weight Changes | link | CRP | 7 | 0.062 |
Malnutrition NOS | link | CRP | 7 | 0.062 |
Ovarian Cysts | link | CRP | 7 | 0.073 |
Polycystic Ovary Syndrome | link | CRP | 7 | 0.075 |
Acute abdomen | link | CRP | 7 | 0.517 |
Liver Diseases | link | GGT1 | 7 | 0.010 |
Hepatitis | link | GGT1 | 7 | 0.100 |
diabetes mellitus type 2 and obesity | link | GGT1 | 7 | 0.217 |
Lymphoma | link | FAS | 7 | 1.47e-08 |
Lupus erythematosus | link | FAS | 7 | 3.60e-05 |
Lupus Erythematosus, Systemic | link | FAS | 7 | 3.60e-05 |
Lymphoma, Non-Hodgkin | link | FAS | 7 | 1.80e-04 |
Neoplasms, Radiation-Induced | link | FAS | 7 | 0.001 |
Neutropenia | link | FAS | 7 | 0.011 |
Hepatitis C, Chronic | link | FAS | 7 | 0.019 |
Lung Diseases, Interstitial | link | FAS | 7 | 0.021 |
Dry Eye Syndromes | link | FAS | 7 | 0.041 |
Brain Death | link | GDF15 | 7 | 0.012 |
Hyperoxia | link | GDF15 | 7 | 0.869 |
Inflammation | link | CRP | 6 | 1.46e-07 |
Cardiovascular Diseases | link | CRP | 6 | 5.36e-07 |
Hypertension | link | CRP | 6 | 2.06e-04 |
Inflammatory Bowel Diseases | link | CRP | 6 | 5.93e-04 |
Nutrition Disorders | link | CRP | 6 | 7.13e-04 |
Arthritis, Rheumatoid | link | CRP | 6 | 7.27e-04 |
Stroke | link | CRP | 6 | 0.002 |
Stroke NOS | link | CRP | 6 | 0.002 |
Crohn Disease | link | CRP | 6 | 0.005 |
Premature Birth | link | CRP | 6 | 0.019 |
Renal diabetes | link | CRP | 6 | 0.030 |
Lung Diseases, Obstructive | link | CRP | 6 | 0.040 |
heart rate | link | CRP | 6 | 0.044 |
diabetes mellitus type 2 and obesity | link | CRP | 6 | 0.046 |
Pancreatitis | link | CRP | 6 | 0.081 |
Vascular Resistance | link | CRP | 6 | 0.087 |
Ventricular Fibrillation | link | CRP | 6 | 0.220 |
Ventricular Dysfunction | link | CRP | 6 | 0.270 |
Diabetes Mellitus | link | GGT1 | 6 | 0.024 |
Liver Neoplasms | link | GGT1 | 6 | 0.047 |
Diabetes Mellitus, Type 2 | link | GGT1 | 6 | 0.047 |
Arteriosclerosis | link | GGT1 | 6 | 0.052 |
Arterial Occlusive Diseases | link | GGT1 | 6 | 0.052 |
Insulin Resistance | link | GGT1 | 6 | 0.126 |
diastolic blood pressure | link | GGT1 | 6 | 0.149 |
systolic blood pressure | link | GGT1 | 6 | 0.149 |
Coronary Artery Disease | link | GGT1 | 6 | 0.165 |
glomerular filtration rate | link | GGT1 | 6 | 0.618 |
Metabolic Syndrome | link | GPT | 6 | 0.249 |
visceral obesity | link | GPT | 6 | 0.657 |
overall survival | link | FAS | 6 | 1.68e-11 |
Lymphoproliferative Disorders | link | FAS | 6 | 2.10e-07 |
Lymphatic Diseases | link | FAS | 6 | 4.36e-06 |
autoimmunity | link | FAS | 6 | 5.46e-04 |
Leukemia, B-Cell | link | FAS | 6 | 0.003 |
Lymphoma, T-Cell | link | FAS | 6 | 0.005 |
Hepatitis, Chronic | link | FAS | 6 | 0.010 |
Hepatitis B | link | FAS | 6 | 0.011 |
Lymphoma, T-Cell, Cutaneous | link | FAS | 6 | 0.156 |
Hepatitis, Autoimmune | link | FAS | 6 | 0.291 |
Endotoxemia | link | FAS | 6 | 0.310 |
Autoimmune hemolytic anemia NOS | link | FAS | 6 | 0.635 |
Intestinal Diseases | link | IL18R1 | 6 | 0.489 |
Colorectal Neoplasms | link | GDF15 | 6 | 5.77e-04 |
Intestinal Neoplasms | link | GDF15 | 6 | 6.88e-04 |
Eating Disorders | link | GDF15 | 6 | 0.046 |
Scleroderma, Systemic | link | GDF15 | 6 | 0.229 |
Hemolysis | link | GDF15 | 6 | 0.493 |
Anemia, Hypochromic | link | GDF15 | 6 | 0.952 |
Embolism | link | GDF15 | 6 | 0.952 |
Adolescent | link | CRP | 5 | 2.01e-04 |
Female Urogenital Diseases and Pregnancy Complications | link | CRP | 5 | 5.29e-04 |
Obesity | link | CRP | 5 | 6.95e-04 |
Diabetes Mellitus | link | CRP | 5 | 9.09e-04 |
Insulin Resistance | link | CRP | 5 | 0.010 |
Gastroenteritis | link | CRP | 5 | 0.013 |
diastolic blood pressure | link | CRP | 5 | 0.013 |
systolic blood pressure | link | CRP | 5 | 0.013 |
Preterm Infant | link | CRP | 5 | 0.027 |
Pain | link | CRP | 5 | 0.062 |
Menopause | link | CRP | 5 | 0.141 |
Hyperglycemia | link | CRP | 5 | 0.161 |
Cysts | link | CRP | 5 | 0.164 |
Osteoarthritis, Knee | link | CRP | 5 | 0.284 |
Femoral Fractures | link | CRP | 5 | 0.322 |
Aortic Aneurysm, Abdominal | link | CRP | 5 | 0.628 |
Coronary Disease | link | GGT1 | 5 | 0.214 |
Hepatitis, Chronic | link | GGT1 | 5 | 0.770 |
heart rate | link | GGT1 | 5 | 0.778 |
Leukemia | link | FAS | 5 | 4.41e-07 |
Acquired Immunodeficiency Syndrome | link | FAS | 5 | 0.020 |
Occupational Diseases | link | FAS | 5 | 0.128 |
Cervical Intraepithelial Neoplasia | link | FAS | 5 | 0.407 |
Death | link | GDF15 | 5 | 0.004 |
Glioblastoma | link | GDF15 | 5 | 0.110 |
Polyps | link | GDF15 | 5 | 0.631 |
Ectopic pregnancy NOS | link | GDF15 | 5 | 0.969 |
Thalassemia | link | GDF15 | 5 | 0.969 |
Anemia, Iron-Deficiency | link | GDF15 | 5 | 0.974 |
Hemochromatosis | link | GDF15 | 5 | 0.974 |
Spinal Cord Diseases | link | RTN4R | 5 | 0.012 |
Spinal Injuries | link | RTN4R | 5 | 0.832 |
Heart Diseases | link | CRP | 4 | 0.003 |
Male Urogenital Diseases | link | CRP | 4 | 0.007 |
Pathologic Processes | link | CRP | 4 | 0.009 |
Necrosis | link | CRP | 4 | 0.014 |
Diabetes Mellitus, Type 2 | link | CRP | 4 | 0.022 |
Pregnancy | link | CRP | 4 | 0.029 |
Obstetric Labor Complications | link | CRP | 4 | 0.112 |
Pulmonary Disease, Chronic Obstructive | link | CRP | 4 | 0.227 |
Heart Failure | link | CRP | 4 | 0.234 |
Weight gain | link | CRP | 4 | 0.358 |
creatine kinase | link | CRP | 4 | 0.358 |
Sleep Disorders | link | CRP | 4 | 0.364 |
Communicable Diseases | link | CRP | 4 | 0.372 |
Cerebral Hemorrhage | link | CRP | 4 | 0.692 |
Tachycardia | link | CRP | 4 | 0.765 |
Cardiovascular Diseases | link | GGT1 | 4 | 0.290 |
Obesity | link | GGT1 | 4 | 0.327 |
Myocardial Ischemia | link | GGT1 | 4 | 0.705 |
hepatic steatosis | link | GPT | 4 | 0.661 |
Autoimmune Diseases | link | FAS | 4 | 0.002 |
Immunologic Deficiency Syndromes | link | FAS | 4 | 0.002 |
Connective Tissue Diseases | link | FAS | 4 | 0.003 |
HIV Infections | link | FAS | 4 | 0.005 |
Arthritis | link | FAS | 4 | 0.011 |
Arthritis, Rheumatoid | link | FAS | 4 | 0.013 |
Leukemia, Lymphoid | link | FAS | 4 | 0.015 |
Lymphoid leukemia NOS | link | FAS | 4 | 0.015 |
Leukemia, T-Cell | link | FAS | 4 | 0.023 |
Multiple Sclerosis | link | FAS | 4 | 0.028 |
Hepatitis | link | FAS | 4 | 0.044 |
Uterine Cervical Neoplasms | link | FAS | 4 | 0.088 |
Rupture | link | FAS | 4 | 0.106 |
transplant rejection | link | FAS | 4 | 0.154 |
Sepsis | link | FAS | 4 | 0.199 |
Septicemia | link | FAS | 4 | 0.204 |
Autoimmune Thyroid Disease | link | FAS | 4 | 0.251 |
Pregnancy First Trimester | link | FAS | 4 | 0.360 |
Gastrointestinal Diseases | link | GDF15 | 4 | 0.016 |
Neoplasm of unspecified nature of digestive system | link | GDF15 | 4 | 0.036 |
Gastrointestinal Neoplasms | link | GDF15 | 4 | 0.043 |
Urogenital Neoplasms | link | GDF15 | 4 | 0.068 |
Hypertension | link | GDF15 | 4 | 0.117 |
Disease Progression | link | GDF15 | 4 | 0.139 |
Recurrence | link | GDF15 | 4 | 0.296 |
Hypertrophy | link | GDF15 | 4 | 0.497 |
Hemostatic Disorders | link | GDF15 | 4 | 0.550 |
Pulmonary Heart Disease | link | GDF15 | 4 | 0.665 |
Body Weight Changes | link | GDF15 | 4 | 0.671 |
Multiple Sclerosis | link | RTN4R | 4 | 0.139 |
Signs and Symptoms | link | CRP | 3 | 0.037 |
event-free survival | link | CRP | 3 | 0.374 |
Disease Progression | link | CRP | 3 | 0.381 |
progression-free survival | link | CRP | 3 | 0.388 |
Cough | link | CRP | 3 | 0.795 |
Hypertrophy, Left Ventricular | link | CRP | 3 | 0.814 |
Intracranial Hemorrhages | link | CRP | 3 | 0.860 |
Subarachnoid Hemorrhage | link | CRP | 3 | 0.860 |
Vascular Diseases | link | GGT1 | 3 | 0.504 |
Endocrine System Diseases | link | GGT1 | 3 | 0.504 |
Endocrine disorder NOS | link | GGT1 | 3 | 0.504 |
Endocrine disturbance NOS | link | GGT1 | 3 | 0.504 |
Retroviridae Infections | link | FAS | 3 | 0.011 |
Sexually Transmitted Diseases | link | FAS | 3 | 0.011 |
Skin and Connective Tissue Diseases | link | FAS | 3 | 0.011 |
Lentivirus Infections | link | FAS | 3 | 0.011 |
Rheumatic Diseases | link | FAS | 3 | 0.044 |
Joint Diseases | link | FAS | 3 | 0.083 |
Obstetric Labor Complications | link | FAS | 3 | 0.107 |
Premature Birth | link | FAS | 3 | 0.201 |
Demyelinating Diseases | link | FAS | 3 | 0.203 |
Gestational hypertension | link | FAS | 3 | 0.246 |
Hepatitis C | link | FAS | 3 | 0.370 |
Disorder of uterus NOS | link | FAS | 3 | 0.401 |
Uterine Neoplasms | link | FAS | 3 | 0.401 |
Organ Transplantation | link | FAS | 3 | 0.502 |
Pre-Eclampsia | link | FAS | 3 | 0.505 |
Eclampsia | link | FAS | 3 | 0.510 |
Mycosis Fungoides | link | FAS | 3 | 0.832 |
Inflammation | link | GDF15 | 3 | 0.296 |
Pregnancy | link | GDF15 | 3 | 0.667 |
Ischemia | link | GDF15 | 3 | 0.718 |
Renal diabetes | link | GDF15 | 3 | 0.888 |
Respiratory Tract Diseases | link | CRP | 2 | 0.427 |
Endocrine System Diseases | link | CRP | 2 | 0.524 |
Endocrine disorder NOS | link | CRP | 2 | 0.524 |
Endocrine disturbance NOS | link | CRP | 2 | 0.524 |
Recurrence | link | CRP | 2 | 0.743 |
treatment related mortality | link | CRP | 2 | 0.992 |
Pregnancy Complications | link | FAS | 2 | 0.656 |
Male Urogenital Diseases | link | GDF15 | 2 | 0.579 |
Hematologic Diseases | link | GDF15 | 2 | 0.767 |
Nutrition Disorders | link | GDF15 | 2 | 0.934 |
Vascular Diseases | link | GDF15 | 2 | 0.954 |
Central Nervous System Diseases | link | RTN4R | 2 | 0.792 |
GLAD4U drugs | ||||
Allergen extracts | link | IL18R1 | 77 | 0.946 |
Polymyxins | link | CRP | 54 | 1.18e-07 |
polymyxin b sulfate | link | CRP | 53 | 2.69e-06 |
nystatin | link | FAS | 33 | 1.63e-06 |
Inflammation And Infection Detection | link | CRP | 30 | 5.59e-04 |
acetone | link | GGT1 | 28 | 0.064 |
serum albumin | link | CRP | 27 | 3.60e-12 |
Interleukins | link | IL18R1 | 27 | 5.25e-08 |
interferons | link | IL18R1 | 25 | 1.19e-06 |
bilirubin | link | GGT1 | 22 | 0.002 |
Fibrinogen | link | CRP | 21 | 1.07e-12 |
Viral Vaccines | link | IL18R1 | 19 | 0.543 |
aminocaproic acid | link | GGT1 | 18 | 0.609 |
antithymocyte globulin | link | FAS | 18 | 0.075 |
apixaban | link | GDF15 | 18 | 0.961 |
human serum albumin | link | CRP | 17 | 2.62e-06 |
Lipid Modifying Agents | link | CRP | 17 | 0.105 |
antivirals | link | IL18R1 | 17 | 1.90e-04 |
Androgens And Female Sex Hormones In Combination | link | CRP | 16 | 0.524 |
Ultrasound Contrast Media | link | CRP | 16 | 0.524 |
Glucarpidase | link | GGT1 | 16 | 0.624 |
trifluoperazine | link | FAS | 16 | 0.003 |
Immunostimulants | link | IL18R1 | 16 | 0.122 |
Tests for renal function | link | CRP | 15 | 2.22e-04 |
Tumor necrosis factor alpha (TNF-alpha) inhibitors | link | FAS | 15 | 0.00e+00 |
Antiinfectives | link | IL18R1 | 15 | 3.34e-04 |
Vaccines | link | IL18R1 | 15 | 0.733 |
atorvastatin | link | CRP | 14 | 0.001 |
Antibacterials For Systemic Use | link | CRP | 14 | 0.547 |
vancomycin | link | CRP | 14 | 0.547 |
Antiseptics And Disinfectants | link | FAS | 13 | 0.028 |
epipodophyllotoxin | link | FAS | 12 | 7.22e-08 |
podofilox | link | FAS | 12 | 7.22e-08 |
Bone morphogenetic proteins | link | GDF15 | 12 | 5.26e-06 |
streptomycin | link | CRP | 11 | 0.603 |
bilirubin | link | GPT | 11 | 0.116 |
etoposide | link | FAS | 11 | 4.83e-08 |
phospholipids | link | ENPP7 | 11 | 1.23e-04 |
ginseng | link | RTN4R | 11 | 0.469 |
aspirin | link | CRP | 10 | 0.020 |
cellulose | link | GGT1 | 10 | 0.814 |
hmg coa reductase inhibitors | link | CRP | 9 | 0.007 |
Fibrates | link | CRP | 9 | 0.080 |
Tests for diabetes | link | CRP | 8 | 0.004 |
metformin | link | CRP | 8 | 0.098 |
simvastatin | link | CRP | 8 | 0.106 |
lovastatin | link | CRP | 8 | 0.109 |
omega-3 polyunsaturated fatty acids | link | CRP | 8 | 0.310 |
pravastatin | link | CRP | 8 | 0.318 |
protein supplements | link | CRP | 8 | 0.325 |
l-alanine | link | GGT1 | 8 | 0.048 |
Drugs used in alcohol dependence | link | GPT | 8 | 0.434 |
doxorubicin | link | FAS | 8 | 5.72e-05 |
Drugs For Functional Gastrointestinal Disorders | link | GDF15 | 8 | 0.216 |
Antifibrinolytics | link | CRP | 7 | 0.345 |
Corticosteroids For Systemic Use | link | CRP | 7 | 0.692 |
glucose | link | GGT1 | 7 | 0.001 |
oxygen | link | GGT1 | 7 | 0.003 |
papain | link | GGT1 | 7 | 0.904 |
starch | link | GPT | 7 | 0.500 |
Proteinase inhibitors | link | FAS | 7 | 2.46e-10 |
highly active antiretroviral therapy (haart) | link | FAS | 7 | 0.011 |
Immunoglobulins | link | IL18R1 | 7 | 0.731 |
immune globulin | link | IL18R1 | 7 | 0.731 |
Cardiac Therapy | link | CRP | 6 | 0.005 |
Antiinflammatory Agents | link | CRP | 6 | 0.017 |
Antihemorrhagics | link | CRP | 6 | 0.097 |
creatine | link | CRP | 6 | 0.162 |
triglycerides | link | GGT1 | 6 | 0.112 |
protease inhibitors | link | FAS | 6 | 1.88e-07 |
Alkylating Agents | link | FAS | 6 | 0.001 |
docetaxel | link | GDF15 | 6 | 0.834 |
Blood coagulation factors | link | CRP | 5 | 5.62e-04 |
triglycerides | link | CRP | 5 | 0.034 |
rosuvastatin | link | CRP | 5 | 0.524 |
alteplase | link | CRP | 5 | 0.547 |
All Other Therapeutic Products | link | CRP | 5 | 0.821 |
Other therapeutic products | link | CRP | 5 | 0.821 |
bnp-32 | link | CRP | 5 | 0.839 |
nesiritide | link | CRP | 5 | 0.839 |
sugar | link | GGT1 | 5 | 0.036 |
glucose | link | GPT | 5 | 0.010 |
Xanthines | link | GPT | 5 | 0.683 |
Immunoglobulins | link | FAS | 5 | 6.33e-07 |
immune globulin | link | FAS | 5 | 6.33e-07 |
Antiinfectives | link | FAS | 5 | 2.00e-06 |
antivirals | link | FAS | 5 | 3.80e-05 |
glucose | link | CRP | 4 | 0.023 |
sugar | link | CRP | 4 | 0.023 |
Diagnostic Agents | link | CRP | 4 | 0.433 |
Other Diagnostic Agents | link | CRP | 4 | 0.620 |
Tests for pancreatic function | link | CRP | 4 | 0.856 |
icosapent | link | CRP | 4 | 0.856 |
l-glutamine | link | GGT1 | 4 | 0.719 |
Liver therapy | link | GPT | 4 | 0.514 |
Monoclonal antibodies | link | FAS | 4 | 7.18e-04 |
interferons | link | FAS | 4 | 0.005 |
Immunosuppressants | link | FAS | 4 | 0.010 |
biotin | link | FAS | 4 | 0.057 |
oxaliplatin | link | FAS | 4 | 0.634 |
trichostatin A | link | GDF15 | 4 | 0.891 |
Interleukins | link | CRP | 3 | 0.308 |
antimetabolites | link | CRP | 3 | 0.551 |
Vasodilators Used In Cardiac Diseases | link | CRP | 3 | 0.998 |
bilirubin | link | CRP | 3 | 0.998 |
sugar | link | GPT | 3 | 0.195 |
Tumour Detection | link | GDF15 | 3 | 0.977 |
Other hormones | link | CRP | 2 | 0.727 |
l-leucine | link | RTN4R | 2 | 0.370 |
KEGG pathways | ||||
Sphingolipid metabolism | link | ENPP7 | 136 | 0.00e+00 |
Glutathione metabolism | link | GGT1 | 85 | 0.00e+00 |
Taurine and hypotaurine metabolism | link | GGT1 | 67 | 6.33e-06 |
Inflammatory bowel disease (IBD) | link | IL18R1 | 40 | 0.007 |
2-Oxocarboxylic acid metabolism | link | GPT | 34 | 1.37e-05 |
Arachidonic acid metabolism | link | GGT1 | 32 | 1.38e-10 |
Biosynthesis of amino acids | link | GPT | 15 | 4.17e-07 |
Cytokine-cytokine receptor interaction | link | IL18R1 | 15 | 0.002 |
Carbon metabolism | link | GPT | 13 | 2.20e-08 |
Apoptosis | link | FAS | 12 | 0.00e+00 |
TNF signaling pathway | link | FAS | 11 | 1.49e-11 |
Natural killer cell mediated cytotoxicity | link | FAS | 10 | 4.69e-10 |
Necroptosis | link | FAS | 9 | 4.90e-11 |
Chagas disease (American trypanosomiasis) | link | FAS | 9 | 2.54e-07 |
Platinum drug resistance | link | FAS | 9 | 9.39e-06 |
African trypanosomiasis | link | FAS | 9 | 0.006 |
Kaposi sarcoma-associated herpesvirus infection | link | FAS | 8 | 4.90e-11 |
Allograft rejection | link | FAS | 8 | 0.007 |
Alanine, aspartate and glutamate metabolism | link | GPT | 7 | 0.261 |
Human cytomegalovirus infection | link | FAS | 7 | 1.90e-10 |
Epstein-Barr virus infection | link | FAS | 7 | 2.77e-10 |
Human immunodeficiency virus 1 infection | link | FAS | 7 | 3.67e-09 |
Hepatitis B | link | FAS | 7 | 6.57e-07 |
Measles | link | FAS | 7 | 1.35e-06 |
Type I diabetes mellitus | link | FAS | 7 | 0.012 |
Arginine biosynthesis | link | GPT | 6 | 0.882 |
Proteoglycans in cancer | link | FAS | 6 | 1.47e-08 |
Herpes simplex infection | link | FAS | 6 | 2.54e-07 |
Influenza A | link | FAS | 6 | 6.92e-07 |
Non-alcoholic fatty liver disease (NAFLD) | link | FAS | 6 | 9.39e-06 |
p53 signaling pathway | link | FAS | 6 | 0.003 |
Graft-versus-host disease | link | FAS | 6 | 0.046 |
Alzheimer disease | link | FAS | 5 | 1.36e-04 |
Autoimmune thyroid disease | link | FAS | 5 | 0.063 |
MAPK signaling pathway | link | FAS | 4 | 3.11e-04 |
Cytokine-cytokine receptor interaction | link | GDF15 | 4 | 0.019 |
Pathways in cancer | link | FAS | 3 | 1.13e-04 |
Human papillomavirus infection | link | FAS | 3 | 0.002 |
Cytokine-cytokine receptor interaction | link | FAS | 3 | 0.005 |
Molecular function GO-terms | ||||
transferase activity, transferring nitrogenous groups | link | GPT | 33 | 4.04e-04 |
cytokine receptor activity | link | IL18R1 | 29 | 0.274 |
cytokine binding | link | IL18R1 | 21 | 0.361 |
exopeptidase activity | link | GGT1 | 16 | 8.20e-05 |
lipoprotein particle receptor binding | link | CRP | 15 | 0.152 |
protein-lipid complex binding | link | CRP | 14 | 0.152 |
phosphoric ester hydrolase activity | link | ENPP7 | 10 | 0.032 |
sphingolipid binding | link | RTN4R | 9 | 0.328 |
glycolipid binding | link | RTN4R | 9 | 0.328 |
cofactor binding | link | GPT | 7 | 1.33e-10 |
vitamin binding | link | GPT | 7 | 0.021 |
transferase activity, transferring acyl groups | link | GGT1 | 5 | 0.286 |
cytokine receptor binding | link | GDF15 | 4 | 0.076 |
glycosaminoglycan binding | link | RTN4R | 3 | 0.214 |
sulfur compound binding | link | RTN4R | 3 | 0.318 |
Reactome pathways | ||||
Glutathione conjugation | link | GGT1 | 150 | 0.00e+00 |
Interleukin-37 signaling | link | IL18R1 | 124 | 6.56e-04 |
Aflatoxin activation and detoxification | link | GGT1 | 115 | 2.10e-11 |
Sphingolipid metabolism | link | ENPP7 | 103 | 0.00e+00 |
CASP8 activity is inhibited | link | FAS | 94 | 0.00e+00 |
Regulation by c-FLIP | link | FAS | 94 | 0.00e+00 |
Dimerization of procaspase-8 | link | FAS | 94 | 0.00e+00 |
Creation of C4 and C2 activators | link | CRP | 85 | 2.44e-12 |
Initial triggering of complement | link | CRP | 84 | 0.00e+00 |
Glutathione synthesis and recycling | link | GGT1 | 82 | 2.48e-05 |
Caspase activation via Death Receptors in the presence of ligand | link | FAS | 65 | 0.00e+00 |
Glycosphingolipid metabolism | link | ENPP7 | 64 | 4.30e-06 |
Regulation of necroptotic cell death | link | FAS | 57 | 0.00e+00 |
Phase II - Conjugation of compounds | link | GGT1 | 56 | 0.00e+00 |
Complement cascade | link | CRP | 52 | 0.00e+00 |
RIPK1-mediated regulated necrosis | link | FAS | 52 | 0.00e+00 |
Regulated Necrosis | link | FAS | 52 | 0.00e+00 |
Interleukin-1 family signaling | link | IL18R1 | 50 | 3.34e-10 |
Caspase activation via extrinsic apoptotic signalling pathway | link | FAS | 47 | 0.00e+00 |
Synthesis of Leukotrienes (LT) and Eoxins (EX) | link | GGT1 | 35 | 0.198 |
TP53 Regulates Transcription of Death Receptors and Ligands | link | FAS | 31 | 1.87e-04 |
Biological oxidations | link | GGT1 | 30 | 0.00e+00 |
Arachidonic acid metabolism | link | GGT1 | 26 | 2.16e-04 |
TP53 Regulates Transcription of Cell Death Genes | link | FAS | 15 | 1.45e-05 |
Signaling by Interleukins | link | IL18R1 | 15 | 2.60e-06 |
Death Receptor Signalling | link | FAS | 13 | 3.29e-14 |
Amino acid synthesis and interconversion (transamination) | link | GPT | 10 | 0.526 |
Apoptosis | link | FAS | 10 | 1.02e-11 |
Programmed Cell Death | link | FAS | 10 | 1.27e-11 |
Fatty acid metabolism | link | GGT1 | 8 | 0.064 |
p75 NTR receptor-mediated signalling | link | RTN4R | 4 | 0.066 |
Metabolism of amino acids and derivatives | link | GPT | 3 | 0.233 |
Transcriptional Regulation by TP53 | link | FAS | 3 | 0.020 |
Death Receptor Signalling | link | RTN4R | 3 | 0.094 |
Wikipathways | ||||
Glutathione metabolism | link | GGT1 | 82 | 0.00e+00 |
Cori Cycle | link | GPT | 33 | 0.002 |
Apoptosis Modulation by HSP70 | link | FAS | 33 | 1.42e-10 |
Nanomaterial induced apoptosis | link | FAS | 28 | 7.34e-09 |
Selective expression of chemokine receptors during T-cell polarization | link | IL18R1 | 27 | 0.926 |
NRF2 pathway | link | GGT1 | 24 | 0.00e+00 |
Human Complement System | link | CRP | 23 | 0.00e+00 |
Alanine and aspartate metabolism | link | GPT | 22 | 0.091 |
Fas Ligand (FasL) pathway and Stress induction of Heat Shock Proteins (HSP) regulation | link | FAS | 20 | 3.57e-11 |
Apoptosis Modulation and Signaling | link | FAS | 17 | 0.00e+00 |
Apoptosis | link | FAS | 17 | 0.00e+00 |
Eicosanoid Synthesis | link | GGT1 | 16 | 0.285 |
Photodynamic therapy-induced AP-1 survival signaling. | link | FAS | 16 | 3.46e-09 |
IL-18 signaling pathway | link | IL18R1 | 15 | 2.21e-04 |
Selenium Micronutrient Network | link | GGT1 | 13 | 5.06e-04 |
Urea cycle and associated pathways | link | GPT | 13 | 0.198 |
Nuclear Receptors Meta-Pathway | link | GGT1 | 11 | 6.27e-14 |
Vitamin D-sensitive calcium signaling in depression | link | GGT1 | 10 | 0.622 |
Alzheimers Disease | link | FAS | 10 | 2.50e-07 |
Hepatitis B infection | link | FAS | 8 | 3.25e-08 |
Spinal Cord Injury | link | RTN4R | 8 | 5.00e-07 |
Allograft Rejection | link | FAS | 7 | 3.03e-04 |
DNA Damage Response | link | FAS | 7 | 4.27e-04 |
miRNA Regulation of DNA Damage Response | link | FAS | 7 | 4.94e-04 |
Nonalcoholic fatty liver disease | link | FAS | 6 | 2.06e-05 |
T-Cell antigen Receptor (TCR) Signaling Pathway | link | FAS | 6 | 0.002 |
Control of immune tolerance by vasoactive intestinal peptide | link | FAS | 6 | 0.425 |
IL-18 signaling pathway | link | FAS | 4 | 2.12e-04 |
MAPK Signaling Pathway | link | FAS | 4 | 2.45e-04 |
VEGFA-VEGFR2 Signaling Pathway | link | FAS | 3 | 0.002 |
Adipogenesis | link | FAS | 3 | 0.111 |
Genes involved in male infertility | link | FAS | 2 | 0.526 |
Epithelial to mesenchymal transition in colorectal cancer | link | GDF15 | 2 | 0.700 |
22q11.2 Deletion Syndrome | link | RTN4R | 2 | 0.939 |
Circadian rhythm related genes | link | FAS | 1 | 0.896 |
Over-representation analysis (ORA) conducted using WebGestaltR (see
tool-publication here).
Enriched terms are calculated based on the supplied targets as a
collected group against all transcripts/proteins measured in
RHAPSODY.
Significant terms with a FDR-adjusted p-value < 0.05 are shown in
blue,
while non-significant terms are shown in gray. The
genes/proteins affiliated with the term are shown to the right of the
barplot.
Unfortunately, the analysis will not always have an output. In these
cases the following error message will be shown:
Unfortunately, no enriched GO-terms were found for the selected targets.
ATC codes | Drug groups | Target type | Pharmacological action | Evidence for interaction | |
---|---|---|---|---|---|
CRELD1 | |||||
– | – | – | – | – | – |
CRP | |||||
CRx-139 | – | Investigational | Target | Unknown | link |
N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium | – | Experimental | Target | Unknown | link |
ENPP7 | |||||
– | – | – | – | – | – |
FAS | |||||
– | – | – | – | – | – |
GDF15 | |||||
– | – | – | – | – | – |
GGT1 | |||||
Glutathione | V03AB32 | Approved, Investigational, Nutraceutical | Target | Unknown | link |
GPT | |||||
Alanine | – | Nutraceutical | Target | Unknown | link |
Glutamic acid | A09AB01 | Approved, Nutraceutical | Target | Unknown | link |
Phenelzine | N06AF03 | Approved | Target | Unknown | link |
Pyridoxal phosphate | A11HA06 | Approved, Investigational, Nutraceutical | Target | Unknown | link |
IL18R1 | |||||
– | – | – | – | – | – |
RTN4R | |||||
– | – | – | – | – | – |
Table of target-drug interactions from DrugBank:
ATC codes: Associated ATC code(s). For further information on the ATC system, see the WHO Collaborating Centre for Drug Statistics’ website.
Drug groups: Drugs are categorized by group determined by their drug development status.:
Target type: Protein targets of drug action, enzymes that are inhibited/induced or involved in metabolism, and carrier or transporter proteins involved in movement of the drug across biological membranes. Colored according to type using color scheme from DrugBank.
Pharmacological action:
Evidence for interaction: Link to the target-drug interaction information on the DrugBank website with references to primary literature on the interaction.
Antibody count from PHAROS (data originates from antibodypedia).
The novelty scores shown here is pulled from PHAROS. This score is calculated from text mining results using the formula \(N_{i} = \frac{1}{\sum \frac{1}{T_{k}}}\), where \(N_{i}\) is the novelty score for the target \(i\) and \(T_{k}\) is the number of targets in abstracts \(k\). The \(\log_{10}\) value of \(N_{i}\) is reported to avoid too high skewness in the data. A more negative value should be interpreted as lower novelty, i.e. the target has been studied/reported more and the target is less novel.
This report is intended to provide objective measures that can be
used to perform informed biomarker prioritization.
It incorporates experimental RHAPSODY data, public data from multiple
databases, data from incorporated R-libraries, and in-house generated
text-mining data.
RHAPSODY data
Public data
In-house generated data
Database | Version | Version release date | Download date |
---|---|---|---|
DrugBank | 5.1.9 | 2022-01-04 | 2022-07-18 |
HPA | 21.1 | 2022-05-31 | 2022-08-04 |
Open Targets | 22.06 | 2022-06-24 | 2022-08-04 |
PHAROS | TCRD v6.12.4 | 2021-10-29 | 2022-01-28 |
UniProt | 2022_03 | 2022-08-03 | 2022-08-04 |
## R version 4.2.1 (2022-06-23)
## Platform: x86_64-apple-darwin17.0 (64-bit)
## Running under: macOS Big Sur ... 10.16
##
## Matrix products: default
## BLAS: /Library/Frameworks/R.framework/Versions/4.2/Resources/lib/libRblas.0.dylib
## LAPACK: /Library/Frameworks/R.framework/Versions/4.2/Resources/lib/libRlapack.dylib
##
## locale:
## [1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8
##
## attached base packages:
## [1] stats graphics grDevices utils datasets methods base
##
## other attached packages:
## [1] WebGestaltR_0.4.4 EnvStats_2.7.0 tidygraph_1.2.2 ggraph_2.1.0
## [5] Cairo_1.6-0 patchwork_1.1.2 ggnewscale_0.4.8 RColorBrewer_1.1-3
## [9] ggrepel_0.9.1 formattable_0.2.1 kableExtra_1.3.4 writexl_1.4.1
## [13] readxl_1.4.2 knitr_1.40 janitor_2.1.0 forcats_1.0.0
## [17] stringr_1.5.0 dplyr_1.1.0 purrr_1.0.1 readr_2.1.4
## [21] tidyr_1.3.0 tibble_3.2.0 ggplot2_3.4.1 tidyverse_1.3.2
##
## loaded via a namespace (and not attached):
## [1] googledrive_2.0.0 colorspace_2.0-3 ellipsis_0.3.2
## [4] rprojroot_2.0.3 snakecase_0.11.0 fs_1.5.2
## [7] rstudioapi_0.14 farver_2.1.1 graphlayouts_0.8.3
## [10] bit64_4.0.5 fansi_1.0.3 lubridate_1.9.2
## [13] xml2_1.3.3 codetools_0.2-18 doParallel_1.0.17
## [16] cachem_1.0.6 polyclip_1.10-4 jsonlite_1.8.4
## [19] apcluster_1.4.10 broom_1.0.4 dbplyr_2.3.1
## [22] ggforce_0.4.1 compiler_4.2.1 httr_1.4.5
## [25] backports_1.4.1 Matrix_1.5-1 fastmap_1.1.0
## [28] gargle_1.2.1 cli_3.4.1 tweenr_2.0.2
## [31] htmltools_0.5.3 tools_4.2.1 igraph_1.3.5
## [34] gtable_0.3.1 glue_1.6.2 doRNG_1.8.2
## [37] Rcpp_1.0.9 cellranger_1.1.0 jquerylib_0.1.4
## [40] vctrs_0.5.2 svglite_2.1.0 iterators_1.0.14
## [43] xfun_0.34 ps_1.7.1 rvest_1.0.3
## [46] timechange_0.2.0 lifecycle_1.0.3 rngtools_1.5.2
## [49] googlesheets4_1.0.1 MASS_7.3-58.1 scales_1.2.1
## [52] vroom_1.6.0 hms_1.1.2 parallel_4.2.1
## [55] curl_4.3.3 yaml_2.3.6 gridExtra_2.3
## [58] sass_0.4.2 stringi_1.7.8 highr_0.9
## [61] foreach_1.5.2 rlang_1.0.6 pkgconfig_2.0.3
## [64] systemfonts_1.0.4 evaluate_0.17 lattice_0.20-45
## [67] htmlwidgets_1.5.4 labeling_0.4.2 bit_4.0.4
## [70] tidyselect_1.2.0 processx_3.7.0 here_1.0.1
## [73] plyr_1.8.7 magrittr_2.0.3 R6_2.5.1
## [76] generics_0.1.3 DBI_1.1.3 pillar_1.8.1
## [79] haven_2.5.2 whisker_0.4 withr_2.5.0
## [82] modelr_0.1.10 crayon_1.5.2 utf8_1.2.2
## [85] tzdb_0.3.0 rmarkdown_2.17 viridis_0.6.2
## [88] grid_4.2.1 callr_3.7.2 reprex_2.0.2
## [91] digest_0.6.30 webshot_0.5.4 munsell_0.5.0
## [94] viridisLite_0.4.1 bslib_0.4.0